Clinical trial register · Spain

Clinical Trials in Badalona, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746

Trials with a site in Badalona

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Not yet open

Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma

NCT07858123Asthma

Chiesi Farmaceutici S.p.A.

Phase 3

700

Badalona, Barcelona, Cartagena, Jerez de la Frontera, Madrid, Santiago de Compostela, Valencia

2026-11-16

Not yet open

Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic Leukemia

NCT07862946Acute Lymphobkastic Leukemia, Adult

DrugInotuzumab Ozogamicin

PETHEMA Foundation

Phase 2

Seville, Valencia, Badalona, Barcelona, Madrid, Málaga, Salamanca, San Sebastián

2026-10-30

Recruiting

Study to Evaluate the Safety and Preliminary Efficacy of CD19 CAR-T Cell Therapy (TranspoCART19) in Patients With Refractory Lupus Nephritis

NCT07799116Lupus Nephritis, Lupus Nephritis (LN)

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Phase 1/2

Badalona, Santiago de Compostela, Pamplona, León, Madrid, Murcia, Salamanca, Seville

2026-09-23

Recruiting

Evaluation of Diagnostic Accuracy and Clinical Performance of the UllCORE Bloodstream Infection (BSI) Test

NCT07859852Blood Stream Infection, Blood Stream Infections, Sepsis, Fungemia

Deepull Diagnostics S.L.

Observational

1,500

Badalona, Barcelona

2026-09-21

Recruiting

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

NCT07540988Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

466

Badalona, Barcelona, Córdoba, Galdakao, Granollers, Hospitalet Llobregat, L'Hospitalet de Llobregat, Madrid

2026-09-17

Recruiting

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

NCT07701941Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer

DrugsPatritumab deruxtecan·Trastuzumab deruxtecan

Daiichi Sankyo

Phase 1/2

220

Badalona, Barcelona, Granada, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Santa Cruz de Tenerife

2026-09-17

Not yet open

Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

NCT07247786Non Small Cell Lung Cancer, Respiratory Tract Neoplasm

DrugsFecal Microbiota Transplantation·Durvalumab·Paclitaxel·Carboplatin

Fundación GECP

Phase 2

Alicante, Elche, Badalona, Barcelona, L'Hospitalet de Llobregat, Granada, Santiago de Compostela, Lugo

2026-09-15

Recruiting

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

NCT07648264Secondary Immune Deficiency

DrugHizentra

CSL Behring

Phase 3

Elche, Barcelona, Badalona, Santander, Madrid

2026-09-15

Recruiting

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsImzokitug·Pumitamig·Pemetrexed·Paclitaxel

Bristol-Myers Squibb

Phase 2

160

Badalona, Seville, Barcelona, Madrid, Majadahonda, Málaga

2026-09-10

Recruiting

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

NCT07623161Myelofibrosis, Anemia

DrugElritercept

Takeda

Phase 3

324

Badalona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Málaga, Barcelona, Madrid, Salamanca, Valencia

2026-09-10

Recruiting

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

NCT07192471T-cell NHL (PTCL or CTCL)

Kyowa Kirin, Inc.

Phase 1

Badalona, L'Hospitalet de Llobregat, Pamplona, Madrid

2026-09-02

Not yet open

Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)

NCT06547138Abdominal Aortic Aneurysm, Morbid Obesity

Aesculap AG

Observational

110

Badalona, Calella, Mataró, Santa Coloma de Gramenet

2026-09

Not yet open

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)

DrugsASCT·AZD0120·Melphalan·Lenalidomide

AstraZeneca

Phase 3

750

Badalona, Barcelona, El Palmar, Madrid, Salamanca, Santander, Seville

2026-08-25

Recruiting

A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.

NCT07460986Soft Tissue Sarcoma (STS)

DrugsBexmarilimab·Doxorubicin

MedSIR

Phase 1/2

278

Badalona, Barakaldo, Barcelona, Madrid, Málaga, San Cristóbal de La Laguna, Seville, Zaragoza

2026-08-20

Recruiting

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

NCT07497087Systemic Sclerosis

Boehringer Ingelheim

Phase 3

448

Badalona, Barakaldo, Barcelona, Huelva, L'Hospitalet Del Llobregat, Madrid, Sabadell, Valencia

2026-07-27

Recruiting

SuperCAP Program to Improve Cognition and Daily Functioning in Post-COVID-19 Condition

NCT07530757Post COVID Condition

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Not applicable

100

Badalona

2026-07-15

Recruiting

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC)

DrugsObrixtamig·Etoposide·Carboplatin

Boehringer Ingelheim

Phase 3

390

Badalona, Barcelona, Madrid, Málaga, Pamplona, Santander, Seville, Valencia

2026-07-10

Recruiting

A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD

NCT07683065Plaque Psoriasis, Metabolic Dysfunction-Associated Steatotic Liver Disease

Novartis Pharmaceuticals

Observational

150

Badalona, Barcelona, Madrid, Málaga

2026-07-08

Not yet open

TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma

NCT07507968Esophagogastric Adenocarcinoma

DrugDurvalumab

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2

101

Badalona, Barcelona, Granada, Jaén, Málaga, Oviedo, Pamplona, Valencia

2026-07-01

Not yet open

A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis

NCT07020715Multiple Sclerosis

University Hospital, Antwerp

Phase 2

Badalona

2026-07-01

By invitation

Prediction of Functional Recovery in Patients With Intracerebral Hemorrhage

NCT07728734Intracranial Hemorrhage, Spontaneous

Germans Trias i Pujol Hospital

Observational

1,688

Badalona

2026-07-01

Recruiting

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

NCT07667803Weight Management

DrugElecoglipron

AstraZeneca

Phase 3

4,500

A Coruña, Almería, Badalona, Barcelona, León, Madrid, Santander, Santiago de Compostela

2026-06-29

Recruiting

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

NCT07764978Newly Diagnosed Multiple Myeloma

DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab

AstraZeneca

Phase 3

750

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia

2026-06-26

Recruiting

A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

NCT07650916HIV Infections

DrugsCab Ula·Rpv La·Cabotegravir

ViiV Healthcare

Phase 3

564

Pozuelo de Alarcón, Alicante, Badalona, Barcelona, Burgos, Cartagena Murcia, Córdoba, Elche Alicante

2026-06-25

Recruiting

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

NCT07634471Follicular Lymphoma

DrugsRituximab Biosimilar·MK-1045·Riabni·Ruxience

Merck Sharp & Dohme LLC

Phase 2/3

960

Badalona, Málaga, Barcelona, Madrid, Salamanca

2026-06-22

Recruiting

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

NCT07647328ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Ribociclib

AstraZeneca

Phase 3

150

Badajoz, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Huelva, Jaén, Las Palmas de Gran Canaria

2026-06-15

By invitation

Frequency of Care for Peripherally Inserted Central Vascular Access In the Prevention of Marsi

NCT07697170Colon Cancer, Cancer Pancreas

Institut Català d'Oncologia

Not applicable

150

Badalona

2026-06-10

Recruiting

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

NCT07504458Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA

DrugsArsenic Trioxide·ATRA

Quetzal Therapeutics

Phase 3

150

Palma de Mallorca, Badalona, Barcelona, Cáceres, Málaga, Oviedo, Valencia

2026-06-08

Recruiting

Projecte Benestar 2026: Virtual Reality Program for Healthcare Workers

NCT07649733Burnout, Healthcare Workers, Occupational Stress, Mental Health Issue

Badalona Serveis Assistencials

Not applicable

100

Badalona, Valls

2026-06-08

Recruiting

Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC

NCT07018947Resectable Hepatocellular Carcinoma

DrugAtezolizumab and Bevacizumab

Fundacion Clinic per a la Recerca Biomédica

Phase 2

Badalona, Barcelona, Santander, Córdoba, Girona, Madrid, Puerto de la Torre, Valencia

2026-06-02

Recruiting

An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED

NCT07519902Persistent Corneal Epithelial Defect

DrugCenegermin

Dompé Farmaceutici S.p.A

Phase 3

150

A Coruña, Cardona, Badalona, Barcelona, Madrid, Málaga, Seville, Valencia

2026-06-02

Recruiting

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic

Apollo Therapeutics Ltd

Phase 2

280

Alicante, Badalona, La Paz, Santiago de Compostela, Zaragoza

2026-05-28

Recruiting

A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

NCT07570173B-cell Acute Lymphoblastic Leukemia

DrugsAvtozma·Tyenne·Siltuximab·MK-1045

Merck Sharp & Dohme LLC

Phase 2/3

340

Badalona, Madrid, Salamanca

2026-05-18

Recruiting

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

NCT07517263Cardiovascular Disease and Lipoprotein(a)

DrugPelacarsen

Novartis Pharmaceuticals

Phase 3

5,700

Santiago Compostela, Seville, Badalona, L'Hospitalet de Llobregat, Santander, Cáceres, Reus, A Coruña

2026-05-11

Recruiting

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

NCT07567001Obesity, Heart Failure

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

5,610

Sant Joan Despí, Valencia, A Coruña, Alcorcón, Antequera, Badalona, Barcelona, Bilbao

2026-05-11

Recruiting

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

NCT07441694Myeloproliferative Neoplasms

Incyte Corporation

Phase 1

218

Badalona, Las Palmas de Gran Canaria, Madrid

2026-05-11

Recruiting

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

NCT07415031Solid Tumors

DrugsAdagrasib·Fluorouracil·Leucovorin·Irinotecan

Mirati Therapeutics Inc.

Phase 2

170

A Coruña, Palma, Barcelona, Badalona, Santander, Madrid, Pamplona, Valencia

2026-05-06

Recruiting

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

DrugMK-1045

Merck Sharp & Dohme LLC

Phase 1/2

280

Badalona, Málaga, Barcelona, Madrid

2026-05-03

Recruiting

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

NCT07419295Bladder Cancer

DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

590

Badalona, Santander, Las Palmas de Gran Canaria, Madrid, Barcelona, Seville

2026-04-23

Recruiting

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

NCT07409181Systemic Lupus Erythematosus

DrugBI 3000202

Boehringer Ingelheim

Phase 2

405

Badalona, Barcelona, Galdakao, Madrid, Vitoria-Gasteiz

2026-04-20

Recruiting

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NCT07509307Obesity, Overweight, Osteoarthritis, Knee

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

400

A Coruña, Badalona, Ferrol, Madrid, Málaga, San Sebastián de Los Reyes (Madrid), Santander, Santiago de Compostela

2026-04-20

Recruiting

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

NCT07227311Multiple Myeloma

DrugsBelantamab mafodotin·Velcade·Carfilzomib·Pomalidomide

GlaxoSmithKline

Phase 2

200

Jerez de la Frontera, Badalona, Córdoba, Gijón, Madrid, Málaga, Salamanca, Vitoria-Gasteiz

2026-04-15

Recruiting

Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)

NCT07481175HIV-1

DrugVenetoclax

Thomas Aagaard Rasmussen

Phase 1

Badalona

2026-04-13

Recruiting

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

NCT07481630Obesity, Knee Osteoarthritis (OA)

DrugNNC0487-0111

Novo Nordisk A/S

Phase 3

400

A Coruña, Badalona, Ferrol, Madrid, Málaga, San Sebastián de Los Reyes (Madrid), Santander, Santiago de Compostela

2026-04-13

Recruiting

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

NCT07522073Solid Tumors

DrugINCB161734

Incyte Corporation

Phase 3

588

Badalona, Barcelona, Las Palmas de Gran Canaria, Madrid, Palma de Mallorca, Santander, Seville, Valencia

2026-04-09

Not yet open

Extended Versus Short Prehabilitation Programme for Patients With Advanced Ovarian Cancer Undergoing Major Surgery

NCT07509814Ovarian Cancer With Peritoneal Carcinosis

Hospital Clinic of Barcelona

Not applicable

225

Badalona, Barcelona, Madrid, Pamplona, Valencia

2026-04-01

Recruiting

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

NCT07407933Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma

DrugsTam-Peli·Atezolizumab

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1/2

118

Badajoz, Badalona, Barcelona, Girona, Madrid, Manresa, Seville, Valencia

2026-03-31

Recruiting

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus

Hoffmann-La Roche

Phase 3

1,600

Badalona, A Coruña, Ferrol, Pozuelo de Alarcón, Barcelona, Madrid, Málaga, Seville

2026-03-23

Recruiting

Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant Volume

NCT07528781Moderate or Severe Mitral Regurgitation

Germans Trias i Pujol Hospital

Observational

200

Badalona

2026-03-17

Recruiting

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

NCT07194382Idiopathic Pulmonary Fibrosis (IPF)

Avalyn Pharma Inc.

Phase 2

160

Badalona, Granollers, Santander, Barcelona, Madrid, Málaga

2026-03-10

Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849CRC (Colorectal Cancer)

DrugsINCA33890·Folfox·Bevacizumab

Incyte Corporation

Phase 3

700

Badalona, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Palma de Mallorca, Pamplona, Pozuelo de Alarcón

2026-03-05

Recruiting

Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain

NCT07624838CD30-Positive Peripheral T-Cell Lymphoma

DrugBrentuximab Vedotin

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Observational

100

A Coruña, Palma de Mallorca, Badalona, Barcelona, L'Hospitalet de Llobregat, Sant Joan Despí, Santander, Jerez de la Frontera

2026-02-15

Recruiting

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

NCT07202546HIV Infections

DrugsVH4524184·Dovato·Dolutegravir/Lamivudine

ViiV Healthcare

Phase 2

186

A Coruña, Alicante, Almería, Badalona, Barcelona, Elche Alicante, Getafe, Granada

2026-02-11

Recruiting

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

NCT07258511Multiple Myeloma

DrugsRamantamig·Teclistamab

Janssen Research & Development, LLC

Phase 3

400

Badalona, Barcelona, Granada, Madrid, Pozuelo de Alarcón, Salamanca, Usansolo, Valencia

2026-02-04

Recruiting

Study of the Brain's Natural Cleaning System in Potential Organ Donors.

NCT07682155Anatomical Description

Germans Trias i Pujol Hospital

Not applicable

Badalona

2026-02-01

Recruiting

Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis

NCT07332091Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis

CSL Behring

Phase 2

Badalona, Barcelona, LAS Palmas de GC, Madrid, Majadahonda, Manresa, Seville

2026-01-22

Recruiting

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT07095452Multiple Myeloma

DrugsEtentamig·Daratumumab·Lenalidomide·Dexamethasone

AbbVie

Phase 2/3

680

Santiago de Compostela, Badalona, Santander, Las Palmas de Gran Canaria, Pamplona, Barcelona, León, Madrid

2026-01-08

Recruiting

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

NCT07221357Untreated, Unresectable, or Metastatic Colorectal Cancer

DrugsPumitamig·Folfox·Bevacizumab

Bristol-Myers Squibb

Phase 2/3

990

Santiago de Compostela, Barcelona, Madrid, Pamplona, Badalona, Elche (alicante), Málaga, Salamanca

2025-12-31

Recruiting

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

NCT07104565Immune Thrombocytopenia

Incyte Corporation

Phase 2

Badalona, Madrid

2025-12-29

Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

NCT07218809Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin

AstraZeneca

Phase 3

1,100

A Coruña, Badalona, Barcelona, Córdoba, Donostia / San Sebastian, Girona, L'Hospitalet de Llobregat, Madrid

2025-12-29

Recruiting

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

NCT06932562Multiple Myeloma

DrugsLinvoseltamab·Daratumumab·Lenalidomide·Dexamethasone

European Myeloma Network B.V.

Phase 3

1,000

Badalona, Barcelona, Madrid, Santander, Valencia

2025-12-23

Active, closed

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR

DrugZipalertinib

Taiho Oncology, Inc.

Phase 3

360

Palma de Mallorca, Badalona, Barcelona, Sabadell, Granada, Las Palmas de Gran Canaria, Lugo, Madrid

2025-12-22

Recruiting

Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions

NCT07190690Coronary Artery Disease

Fundación EPIC

Not applicable

2,100

Alicante, Badalona, Barakaldo, Barcelona, Castelló, Donostia / San Sebastian, El Palmar, Fuencarral-El Pardo

2025-12-19

Recruiting

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT07225946Prostatic Neoplasms, Castration-Resistant

DrugsPasritamig·Prednisone/Prednisolone·Docetaxel

Janssen Research & Development, LLC

Phase 3

800

Badalona, Madrid, Murcia, Seville, Valencia, Zaragoza

2025-12-19

Recruiting

Inhaled Sedation in Critically Ill Patients

NCT07000526Sedation, Airway Extubation

DrugsIsoflurane·Propofol

Instituto de Investigación Hospital Universitario La Paz

Phase 4

620

Orihuela, Arrecife, Galdakao, Albacete, Badalona, Barcelona, Jaén, Lleida

2025-12-15

Recruiting

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis

DrugsVepugratinib·Pembrolizumab

Eli Lilly and Company

Phase 3

450

Badajoz, Badalona, Barakaldo, Barcelona, Córdoba, Elche, Girona, Hospitalet

2025-12-12

Recruiting

Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selution Iberia Registry

NCT07256249Cardiovascular Diseases

Fundación EPIC

Observational

960

Vilagarcía de Arousa, Badalona, Barcelona, León, San Cristóbal de La Laguna, Santander, Santiago de Compostela, Seville

2025-12-11

Recruiting

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

NCT07285213Clostridioides Difficile Infection

AstraZeneca

Phase 2

230

Alicante, Badalona, Madrid, Majadahonda, Seville

2025-12-10

Recruiting

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

NCT07214779Ovarian Cancer

DrugINCB123667

Incyte Corporation

Phase 3

466

Alava, Badalona, Barcelona, Madrid, Málaga, Oviedo, Palma, Sabadell

2025-12-09

Active, closed

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

NCT07290569Plaque Psoriasis

DrugORKA-001

Oruka Therapeutics, Inc.

Phase 2

160

Badalona, Barcelona, Madrid

2025-12-03

Recruiting

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

NCT07241390Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease

DrugOrforglipron

Eli Lilly and Company

Phase 3

7,140

Almería, Alzira, Badajoz, Badalona, Barcelona, Boadilla del Monte, Lugo, Majadahonda

2025-12-01

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

NCT07223047Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)

DrugsCetuximab·Nab-paclitaxel·Gemcitabine·Pembrolizumab

Bristol-Myers Squibb

Phase 1/2

252

Badalona, Hortaleza

2025-11-25

Recruiting

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

NCT07211958Acute Myeloid Leukemias

DrugRevumenib

Syndax Pharmaceuticals

Phase 3

468

Badalona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Santander, Oviedo, Alicante, Barcelona, Burgos

2025-11-25

Recruiting

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

NCT06948448Colorectal Cancer

DrugsONO-4578·Leucovorin·Opdivo·Adrucil

Ono Pharmaceutical Co., Ltd.

Phase 2

144

Badalona, Barcelona, Córdoba, Madrid, Seville, Málaga, Valencia

2025-11-18

Recruiting

A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa

NCT07284342Advanced Parkinson's Disease

AbbVie

Observational

103

Málaga, Palma, Badalona, Santander, Cartagena, Gijón, Seville, Almería

2025-11-17

Recruiting

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420Palmoplantar Pustulosis

DrugBimekizumab

UCB Biopharma SRL

Phase 3

320

Alicante, Badalona, Granada, Madrid, Manises, Málaga, Santiago de Compostela, Valencia

2025-11-14

Recruiting

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

NCT06804811NonSegmental Vitiligo

DrugRuxolitinib

Incyte Corporation

Phase 3

250

Alcorcón, Badalona, Barcelona, Esplugues de Llobregat, Madrid, Zaragoza

2025-11-13

Recruiting

A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy

NCT07785180Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Stemline Therapeutics, Inc.

Observational

140

Albacete, Alicante, Badalona, Burgos, Cáceres, Córdoba, Madrid, Oviedo

2025-10-17

Recruiting

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease

DrugsRetatrutide·Tirzepatide

Eli Lilly and Company

Phase 3

4,500

A Coruña, Badalona, Barcelona, Ferrol, Huelva, Madrid, Palma, Pontevedra

2025-10-15

Recruiting

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

NCT07160725Solid Tumours

DrugPumitamig

Bristol-Myers Squibb

Phase 1/2

540

Málaga, Badalona, Barcelona, Pamplona, Madrid

2025-10-15

Recruiting

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

NCT07190248Non-small Cell Lung Cancer

Drugs) Berahyaluronidase alfa·Calderasib·Paraplatin·Pemetrexed

Merck Sharp & Dohme LLC

Phase 3

675

Badalona, Barcelona, A Coruña, Majadahonda, Valencia, Madrid, Seville

2025-10-08

Recruiting

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857Multiple Myeloma

DrugsCilta-cel·Fludarabine·Cyclophosphamide

Janssen Research & Development, LLC

Phase 2

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Seville

2025-10-03

Recruiting

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)

DrugNNC6019-0001

Novo Nordisk A/S

Phase 3

1,280

A Coruña, Badalona, Barcelona, Bilbao, Córdoba, Donostia / San Sebastian, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria

2025-10-02

Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma

NCT07285590Mantle Cell Lymphoma (MCL)

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, El Palmar, Marbella, Pamplona, Salamanca

2025-09-30

Recruiting

A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

NCT06865417Ulcerative Colitis

DrugFilgotinib

Alfasigma S.p.A.

Phase 3

Badalona, Córdoba

2025-09-29

Recruiting

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma

DrugsPF-08046054·Docetaxel

Pfizer

Phase 3

680

A Coruña, Badalona, Barcelona, Madrid, Badajoz, Granada, Palma, Seville

2025-09-29

Recruiting

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967Plaque Psoriasis

DrugsUstekinumab·Deucravacitinib

Bristol-Myers Squibb

Phase 3

3,040

Badalona, Barcelona, Las Palmas de Gran Canaria, Alcorcón, Málaga, Salamanca, Seville, Madrid

2025-09-22

Recruiting

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

NCT07190222Chronic Obstructive Pulmonary Disease

DrugLunsekimig

Sanofi

Phase 3

942

Zaragoza, Badalona, Santander, Barcelona, Madrid

2025-09-17

Recruiting

A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

NCT07029737Mantle-cell Lymphoma

DrugsLisaftoclax·Acalabrutinib

AstraZeneca

Phase 2

A Coruña, Alcorcón, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Gijón, Madrid

2025-09-05

Recruiting

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsTacabrutideg·Pirtobrutinib

BeOne Medicines

Phase 3

500

Badalona, Burgos, Las Palmas de Gran Canaria, Madrid, Majadahonda, Palma de Mallorca, Seville

2025-09-04

Recruiting

Vestibular Rehabilitation Protocol in Unilateral Vestibular Schwannoma

NCT07364955Vestibular Schwannoma, Vestibular Schwannomas

Albert Torrents Torrero

Not applicable

Badalona

2025-09-01

Recruiting

Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients

NCT07197164COVID - 19, Renal Transplant, SARS CoV 2 Infection

DrugsVeklury·Remdesivir

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Phase 2

Badalona

2025-09-01

Not yet open

Guttmann NeuroRecovery - Viability, Safety, and Efficacy of Intrathecal Wharton's Jelly Mesenchymal Stem Cells and Transcutaneous Spinal Cord Stimulation in Chronic Spinal Cord Injury Rehabilitation

NCT06981338Spinal Cord Injuries (SCI), Spinal Cord Injury, Traumatic Spinal Cord Injuries, Spinal Cord Disease

Institut Guttmann

Phase 1/2

Badalona

2025-09-01

Recruiting

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer

DrugsCapivasertib·Fulvestrant

Relay Therapeutics, Inc.

Phase 3

540

Badajoz, Badalona, Barcelona, Castellon, Cáceres, El Palmar, Girona, Huelva

2025-08-26

Recruiting

An International Observational Study of Adults With Acute Infection

NCT07069400Infectious Disease

University of Minnesota

Observational

1,500

Badalona

2025-08-25

Recruiting

Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

NCT07126236Large B Cell Lymphoma

DrugEpcoritamab

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Phase 2

Seville, Zaragoza, Palma de Mallorca, Burgos, Salamanca, Badalona, Barcelona, Cáceres

2025-08-04

Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336Endometrial Cancer, Malignant Solid Tumour

DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel

AstraZeneca

Phase 3

800

Badalona, Barcelona, Córdoba, El Palmar (Murcia), L'Hospitalet de Llobregat, Madrid, Málaga, Oviedo

2025-08-01

Recruiting

PALACE: Cemiplimab Trial According to ctDNA Levels

NCT06917573Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer, Stage III Non-small Cell Lung Cancer

DrugsCarboplatine·Cemiplimab·Paraplatin·Taxol

Fundación GECP

Phase 2

Alicante, Elche, Badalona, Barcelona, L'Hospitalet de Llobregat, Bilbao, Jerez de la Frontera, Girona

2025-07-29

Recruiting

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

12,800

Castilleja de la Cuesta, Córdoba, Jaén, Málaga, Seville, San Cristóbal de La Laguna, Santander, Badalona

2025-07-25

Recruiting

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

NCT05691244Acute Ischemic Stroke, Cerebral Stroke

DrugSovateltide

Pharmazz, Inc.

Phase 3

514

Badalona, Barcelona, Albacete, Madrid, El Palmar, Seville, Tarragona, A Coruña

2025-07-24

Recruiting

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

11,800

Badalona, Barcelona, Beiro, Córdoba, Galdakao, Huelva, Jaén, Las Palmas de Gran Canaria

2025-07-22

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807Breast Neoplasms

DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda

Merck Sharp & Dohme LLC

Phase 3

1,000

Badalona, Santander, A Coruña, Barcelona, Madrid, Seville

2025-07-21

Recruiting

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive

DrugsNeladalkib·Alectinib

Nuvalent Inc.

Phase 3

450

A Coruña, Badalona, Barcelona, Girona, Madrid, Málaga, Seville

2025-07-17

Recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma

DrugsBevacizumab biosimilar·Calderasib·Mvasi·Erbitux

Merck Sharp & Dohme LLC

Phase 3

477

Badalona, Santander, Las Palmas de Gran Canaria, Oviedo, Barcelona, Madrid, Seville, Valencia

2025-07-16

Recruiting

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

NCT06963827Kidney Disease

DrugMezagitamab

Takeda

Phase 3

347

Badalona, Barakaldo, Pamplona, Barcelona, Madrid, Seville

2025-07-15

Recruiting

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

NCT07013474COVID-19 Infection

DrugsIbuzatrelvir·Veklury·Remdesivir

Pfizer

Phase 3

300

A Coruña, Córdoba, Badalona, Barcelona, Madrid, Vigo, Alicante, Seville

2025-07-14

Recruiting

Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)

NCT07153445Non Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer

DrugsTecentriq·Paraplatin·Taxol·Atezolizumab

Fundación GECP

Phase 2

Alicante, Badalona, Barcelona, Bilbao, Jerez de la Frontera, Girona, Granada, A Coruña

2025-07-08

Recruiting

Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

NCT07045909De Novo Multiple Myeloma, Anitocabtagene Autoleucel

DrugsAnitocabtagene Autoleucel·Isatuximab·Bortezomib·Daratumumab

PETHEMA Foundation

Phase 2

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Santiago de Compostela, Seville

2025-06-30

By invitation

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07007637Hidradenitis Suppurativa

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

835

Alicante, Badalona, Barcelona, Cadiz, Córdoba, Granada, Granollers, Madrid

2025-06-27

Recruiting

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

5,056

Córdoba, Málaga, Las Palmas de Gran Canaria, Badalona, Barcelona, L'Hospitalet de Llobregat, Lleida, A Coruña

2025-06-25

Active, closed

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

NCT06959225Hidradenitis Suppurativa

DrugRuxolitinib

Incyte Corporation

Phase 3

580

Alicante, Badalona, Barcelona, Madrid

2025-06-23

Recruiting

Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.

NCT06856213Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

DrugsCetuximab·Paclitaxel

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Phase 2

Santiago de Compostela, Badalona, Barcelona, Santander, Granada, A Coruña, Lugo, Madrid

2025-06-18

Active, closed

PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

NCT06906822Melanoma

DrugsEnfortumab Vedotin·Pembrolizumab

Grupo Español Multidisciplinar de Melanoma

Phase 2

A Coruña, Badalona, Barcelona, Santander, Madrid, Murcia, Seville, Valencia

2025-06-10

Recruiting

Chronic Insomnia in Non-Cancer Pain Patients

NCT07057232Chronic Non-cancer Pain, Insomnia

Germans Trias i Pujol Hospital

Observational

385

Badalona, Barcelona, Girona, Hospitalet Del Llobregat, Lleida, Sant Joan Despí, Tarragona, Terrassa

2025-06-09

Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,755

A Coruña, Badalona, Barcelona, El Palmar, Girona, Huelva, Jerez de la Frontera, L'Hospitalet de Llobregat

2025-06-09

Active, closed

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 3

Badalona, Barcelona, El Palmar, Esplugues de Llobregat, Granada, Las Palmas de Gran Canaria, Madrid, Málaga

2025-06-04

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

NCT06682988Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancers

DrugsMIRV·Mirvetuximab Soravtansine

AbbVie

Phase 2

110

Badalona, Jaén, El Palmar, Pamplona, Seville, Barcelona, Madrid, Valencia

2025-05-28

Recruiting

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

NCT05815927Oligometastatic Squamous Cell Carcinoma of the Head and Neck

DrugPembrolizumab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

200

Badalona, Barakaldo, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga

2025-05-23

Recruiting

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301Advanced Melanoma

DrugsEIK1001·Keytruda·Pembrolizumab

Eikon Therapeutics

Phase 2/3

740

Santiago de Compostela, Badalona, Barcelona, Santander, Cáceres, Lugo, Girona, Madrid

2025-05-22

Recruiting

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

NCT06947993Atopic Dermatitis

Novartis Pharmaceuticals

Phase 2

224

Badalona, Alicante, Granada, Las Palmas GC, Madrid, Pontevedra

2025-05-16

Active, closed

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

NCT06962280Type 1 Diabetes, Obesity, Overweight

DrugTirzepatide

Eli Lilly and Company

Phase 3

465

Badajoz, Badalona, Barcelona, Madrid, Seville

2025-05-12

Recruiting

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

NCT07227246Intracerebral Hemorrhage

DrugRecombinant Factor VIIa

Joseph Broderick, MD

Phase 3

350

Badalona, Horta, L'Hospitalet de Llobregat, Barcelona, Girona, Lleida, Valladolid

2025-05-06

Recruiting

Spanish Validation of KOQUSS-40 Questionnaire: Assessing QoL of Gastric Cancer Patients After Gastrectomy: SPQUSS-41

NCT07504913Stomach Neoplasms, Validation Study

Parc de Salut Mar

Observational

505

Badalona, Barcelona, L'Hospitalet de Llobregat, Puerto Real, Logroño, Lleida

2025-05-03

Recruiting

Identity-Based Transdiagnostic Therapy for Young People With Anxiety and Depression

NCT06384196Depression, Anxiety

University of Barcelona

Not applicable

138

Badalona, Barcelona

2025-05-02

Recruiting

Validation of a Questionnaire to Measure Cough Severity

NCT06669897Cough

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Observational

100

Badalona, L'Hospitalet de Llobregat, Sabadell, Barcelona

2025-05-01

Not yet open

Autologous Tolerogenic Dendritic Cells (ATDC) for Highly Sensitized Kidney Transplant Recipients

NCT06852625Kidney Transplant Rejection

Fundacion Clinic per a la Recerca Biomédica

Phase 1

Badalona, Barcelona, L'Hospitalet de Llobregat, Zaragoza

2025-05

Recruiting

EMBRACE Tremor BiFUS

NCT06974916Essential Tremor

InSightec

Not applicable

100

Badalona, Móstoles, Pamplona, Valencia

2025-04-22

Recruiting

Impact of IBD Activity on Frailty in Patients Over 60 Years

NCT06844318IBD

Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

Observational

153

Vitoria-Gasteiz, Badalona, L'Hospitalet de Llobregat, Manresa, Mataró, Terrassa, Viladecans, Torrelavega

2025-04-14

Recruiting

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer

DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab

Corcept Therapeutics

Phase 2

270

Badalona, Barcelona, Madrid, Valencia

2025-04-11

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

NCT06868277Carcinoma, Non-Small Cell Lung

DrugsRilvegostomig·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

830

Badajoz, Badalona, Barcelona, Castellon, Granada, Jaén, Lugo, Madrid

2025-04-10

Active, closed

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

NCT06864169Gastrointestinal Cancer

DrugR-DXd

Merck Sharp & Dohme LLC

Phase 2

160

Badalona, Santander, Barcelona, Madrid

2025-04-01

Recruiting

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

NCT06750289Eosinophilic Asthma

AstraZeneca

Phase 3

400

Alcorcón, Alzira (Valencia), Badalona, Barakaldo, Barcelona, Burgos, Cáceres, Granada

2025-03-28

Recruiting

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

NCT06830759Diffuse Large B-cell Lymphoma, Follicular Lymphoma

AbbVie

Observational

700

A Coruña, Badalona, Sabadell, Córdoba, Marbella, Pamplona, Seville, Manises

2025-03-28

Recruiting

The Pivotal Study of RapidPulseTM Aspiration System

NCT06029491Acute Ischemic Stroke

RapidPulse, Inc

Not applicable

170

Alicante, Badalona, Barcelona, Girona, Madrid

2025-03-27

Active, closed

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsEfti·Pemetrexed·Keytruda·Paclitaxel

Immutep S.A.S.

Phase 3

756

Badalona, Barcelona, Córdoba, Madrid, Málaga, Oviedo, Sabadell, Seville

2025-03-21

Recruiting

Predictive Model for Mortality in Older People With Critical Illness

NCT06727903Critical Illness

Consorci Sanitari de l'Alt Penedès i Garraf

Observational

450

Badalona, Sant Pere de Ribes, Barcelona, Girona

2025-03-20

Recruiting

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

NCT06797635Breast Neoplasms, Breast Cancer

DrugsPatritumab deruxtecan·Doxorubicin Hydrochloride·Epirubicin·Adriamycin

Merck Sharp & Dohme LLC

Phase 2

372

Badalona, Madrid, Córdoba

2025-03-20

Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)

DrugsArlo-cel·Carfilzomib·Pomalidomide·Daratumumab

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3

440

Santiago de Compostela, Palma, Badalona, Pamplona, Granada, Salamanca

2025-03-12

Active, closed

An Ophthalmic Safety Study in Patients With Breast Cancer

NCT06767462Ophthalmic Safety in Patients With Breast Cancer

AstraZeneca

Observational

160

Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Leganés, Madrid, Majadahonda, Salamanca

2025-03-05

Recruiting

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

NCT06742723Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

5,000

A Coruña, Almería, Badalona, L'Hospitalet de Llobregat, Majadahonda, Málaga, Palma deMallorca, Pamplona

2025-03-03

Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil

AstraZeneca

Phase 3

840

Badalona, Barcelona, Madrid, Ourense, Santander, Seville, Valencia

2025-03-01

Recruiting

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

600

Alcorcón, Alicante, Badalona, Barcelona, Córdoba, Granada, Las Palmas de Gran Canaria, Madrid

2025-02-28

Recruiting

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

DrugsMomelotinib·Reblozyl·Luspatercept

GlaxoSmithKline

Phase 2

Badalona, Barcelona, Las Palmas, Madrid, Málaga, Valencia

2025-02-28

Recruiting

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer

DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

726

Badalona, Barcelona, Córdoba, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia

2025-02-27

Recruiting

Effectiveness of a multicOmpoNent Behavioural intervenTion to Reduce endocrINe disrUptor Exposure During pErinatal Period (CONTINUE)

NCT07142447Pregnancy, Children

Fundació Institut Germans Trias i Pujol

Not applicable

810

Badalona

2025-02-24

Active, closed

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

Badalona, Pamplona, Burjassot, Madrid, Málaga

2025-02-19

Recruiting

Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

NCT06431633Lung Diseases, Carcinoma, Non-Small-Cell Lung, Resectable Lung Non-Small Cell Carcinoma

DrugsZimberelimab·Sacituzumab Govitecan·Paraplatin·Cisplatin

Fundación GECP

Phase 3

129

Alicante, Elche, Badalona, Barcelona, L'Hospitalet de Llobregat, Bilbao, Jerez de la Frontera, A Coruña

2025-02-04

Recruiting

Follow-up of Spanish Prospective Asthma and Nasal Polyposis Registry

NCT06163807Chronic Asthma

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Observational

1,200

Santiago de Compostela, Badalona, Barcelona, A Coruña, Madrid, Pamplona

2025-02-01

Active, closed

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

588

Cadiz, Badalona, Sabadell, Barcelona, Manises, Valencia, Madrid

2025-01-31

Active, closed

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer

DrugM9140

EMD Serono Research & Development Institute, Inc.

Phase 1/2

184

Córdoba, Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pozuelo de Alarcón, Seville, Valencia

2025-01-29

Recruiting

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsFicerafusp alfa·Keytruda·Pembrolizumab

Bicara Therapeutics

Phase 2/3

650

Badalona, Barcelona, Madrid, Pamplona, Santander, Valencia

2025-01-28

Recruiting

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

NCT06712316Non-small Cell Lung Cancer

DrugsPumitamig·Pemetrexed·Paclitaxel·Carboplatin

BioNTech SE

Phase 2/3

1,580

A Coruña, Badajoz, Badalona, Barcelona, Castellon, Las Palmas de Gran Canaria, León, Lleida

2025-01-07

Recruiting

Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis

NCT06955221Endometrioma, Ultrasound Therapy; Complications, Quality of Life, Pelvic Pain

Hospital Universitari de Bellvitge

Not applicable

288

Palma de Mallorca, Badalona, Igualada, L'Hospitalet de Llobregat, Martorell, Sabadell, Sant Boi de Llobregat, Viladecans

2025-01-01

Recruiting

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

NCT06078384Triple-negative Breast Cancer

DrugsTaxol·Keytruda·Paclitaxel·Pembrolizumab

UNICANCER

Phase 2

354

Alicante, Badalona, Barcelona, El Palmar, Granada, L'Hospitalet de Llobregat, León, Lleida

2024-12-27

Recruiting

Early Palliative Care in Patients With Advanced Lung Cancer Using an e-Health Ecosystem

NCT07039994Non-Small Cell Lung Cancer

Jesús González

Not applicable

200

Badalona, L'Hospitalet de Llobregat

2024-12-24

Active, closed

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

NCT06604715Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC

Phase 1

Badalona, Barcelona, Madrid, Pamplona, Salamanca

2024-12-19

Active, closed

A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

NCT06742190Multifocal Motor Neuropathy (MMN), MMN

DrugsEmpasiprubart·Immunoglobulin·IVIG

argenx

Phase 3

154

Alicante, Badalona, Barcelona, Madrid, Málaga, San Sebastián

2024-12-18

Recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

NCT06727604Graves' Disease

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

240

Badalona, Barcelona, Córdoba, Granada, Madrid, Pamplona, Seville

2024-12-17

Recruiting

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma

DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone

GlaxoSmithKline

Phase 3

520

Badalona, Barcelona, Gijón, Madrid, Málaga, Murcia, Salamanca, Santander

2024-12-16

Active, closed

Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia

NCT06668558Acute Myeloid Leukemia

DrugsAzacitidine·Venetoclax

Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias

Phase 2

Palma de Mallorca, Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Lleida, Tarragona, Terrassa

2024-12-16

Not yet open

Evaluation of Cardioverter Capacity of Amiodarone Pre-electrical Cardioversion in Persistent Atrial Fibrillation

NCT06645249Atrial Fibrillation (AF)

DrugAmiodarone

Institut Investigacio Sanitaria Pere Virgili

Phase 4

122

Badalona, Barcelona, Reus, Santiago de Compostela

2024-12-10

Recruiting

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019Familial Hypercholesterolemia - Heterozygous

DrugInclisiran

Novartis Pharmaceuticals

Phase 3

Elche, Cadiz, Badalona, Esplugues, Pamplona, Barcelona, Málaga, Seville

2024-12-09

Recruiting

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

NCT06679140COVID-19 SARS-CoV-2 Infection

DrugIbuzatrelvir

Pfizer

Phase 3

2,330

A Coruña, Benalmádena, Córdoba, Badalona, Barcelona, Madrid, Vigo, Alicante

2024-12-08

Recruiting

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

NCT06382948Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation

DrugsElacestrant·Everolimus

MedSIR

Phase 3

300

Barcelona, A Coruña, Alicante, Badalona, Bilbao, Burgos, Castellon, Cáceres

2024-12-05

Recruiting

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

NCT06465953Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)

DrugsIvosidenib·Azacitidine

Institut de Recherches Internationales Servier

Phase 3

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia

2024-12-03

Recruiting

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

NCT06472245Patients With Non-Small Cell Lung Cancer

DrugsTedopi·Docetaxel

OSE Immunotherapeutics

Phase 3

363

Palma de Mallorca, Badalona, L'Hospitalet de Llobregat, Barakaldo, A Coruña, Las Palmas de Gran Canaria, Majadahonda, Marbella

2024-12-03

Recruiting

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

NCT06667700Coronavirus Disease (COVID-19)

DrugMolnupiravir

Merck Sharp & Dohme LLC

Phase 3

3,082

Elche, Badalona, Centelles, Barcelona, A Coruña, Cartagena, Madrid, Seville

2024-12-02

Active, closed

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247Leukemia

DrugQuizartinib

Daiichi Sankyo

Phase 3

700

Albacete, Alicante, Badalona, Barcelona, Burgos, Cáceres, Córdoba, Las Palmas

2024-11-19

Active, closed

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

NCT06465329Non-Small Cell Lung Cancer

DrugsMarlotamig·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

120

Badalona, Santander, Las Palmas de Gran Canaria, Pamplona, Madrid, Seville, Valencia, Zaragoza

2024-11-18

Active, closed

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma

NCT06676319Asthma

DrugsBudesonide/Formoterol·Lunsekimig

Sanofi

Phase 2

556

Santiago de Compostela, Badalona, Santander, Barcelona, Madrid, Benalmádena, Girona, Málaga

2024-11-07

Active, closed

Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia

NCT06695832Staphylococcus Aureus Bacteremia

Hospital Universitari de Bellvitge

Observational

369

L'Hospitalet de Llobregat, Badalona, Barcelona

2024-11-01

Not yet open

Acquired Brain Injury and Neurorehabilitation: the Influence of Psychological Characteristics

NCT06661512Brain Injury, Stroke Patients, TBI-Traumatic Brain Injury

Institut Guttmann

Observational

200

Badalona

2024-11

Active, closed

A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)

NCT06519357Mild Cognitive Impairment

DrugLamivudine

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Phase 2

Badalona

2024-10-28

Recruiting

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

NCT06651567Agitation Associated With Alzheimer's Dementia

DrugITI-1284

Intra-Cellular Therapies, Inc.

Phase 2

320

Albacete, Badalona, Málaga, Zamora, Zaragoza

2024-10-22

Recruiting

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT06581432Solid Tumours

DrugZongertinib

Boehringer Ingelheim

Phase 2

588

A Coruña, Badalona, Barcelona, Madrid, Pamplona, Seville, Valencia

2024-10-11

Active, closed

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

NCT06516965Prurigo Nodularis

DrugPovorcitinib

Incyte Corporation

Phase 3

346

Alicante, Badalona, Barcelona, Córdoba, Granada, Madrid, Majadahonda, Manises

2024-10-10

Recruiting

Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients

NCT06634199Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation

DrugDurvalumab

Fundación GECP

Observational

Ferrol, Alicante, Badalona, Barcelona, Bilbao, Ciudad Real, Girona, A Coruña

2024-10-03

Recruiting

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

NCT06492616Breast Cancer

DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole

Stemline Therapeutics, Inc.

Phase 3

4,220

Vigo, Seville, Badalona, Sant Cugat del Vallès, Sant Joan Despí, San Cristóbal de La Laguna, Cáceres, Móstoles

2024-09-27

Active, closed

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

NCT06525220Head and Neck Squamous Cell Carcinoma

DrugsPetosemtamab·Pembrolizumab

Merus B.V.

Phase 3

699

Badalona, Barcelona, Madrid, Marbella, Pamplona, Valencia

2024-09-25

Active, closed

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951Melanoma

DrugsFianlimab·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

151

Granada, Málaga, Palma, Badalona, Barcelona, El Palmar, Oviedo, Madrid

2024-09-18

Active, closed

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)

NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

DrugsABP 234·Pembrolizumab

Amgen

Phase 3

163

A Coruna Galicia, A Coruña, Alicante, Badalona, Barcelona, Jerez de la Frontera, Madrid, Mataró

2024-09-12

Recruiting

Pilot Study of the α Prototype NIMBLE System: Feasibility, Safety, and Initial Performance in Non-Invasive Detection of Coronary In-Stent Restenosis

NCT06968858In-stent Restenosis, Stent Fracture, Stent Complication

Nimble Diagnostics S.L.

Phase 1/2

Badalona

2024-09-12

Recruiting

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

NCT06058585Chronic Kidney Diseases

DrugsFinerenone·Semaglutide

The George Institute

Phase 3

2,000

Badalona, Horta-Guinardó, Valencia

2024-09-04

Recruiting

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation

DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin

Bayer

Phase 3

555

Badalona, Majadahonda, Pamplona, A Coruña, Barcelona, Madrid, Valencia

2024-08-28

Recruiting

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT06500884Multiple Myeloma

DrugsRamantamig·Talquetamab

Janssen Research & Development, LLC

Phase 2

210

Badalona, Barcelona, El Palmar, Jerez de la Frontera, Madrid, Pozuelo de Alarcón, Salamanca

2024-08-26

Active, closed

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

NCT06413498Multiple Myeloma

DrugsAnitocabtagene Autoleucel·Carfilzomib·Pomalidomide·Bortezomib

Kite, A Gilead Company

Phase 3

452

Badalona, Barcelona, El Palmar, Madrid, Pamplona, Salamanca, Santander, Seville

2024-08-23

By invitation

Long-term Safety and Tolerability of BHV-7000

NCT06443463Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2

660

Badalona, L'Hospitalet de Llobregat, Pamplona, Vigo, Barcelona, Granada, Madrid, Málaga

2024-07-30

Active, closed

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)

NCT06355531Progressive Supranuclear Palsy

Ferrer Internacional S.A.

Phase 2

241

A Coruña, Badalona, Barakaldo, Barcelona, Madrid, Pamplona, Seville, Valencia

2024-07-23

Recruiting

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

NCT06252649Metastatic Colorectal Cancer

DrugsLumakras·Sotorasib·Bevacizumab-awwb·Panitumumab

Amgen

Phase 3

450

Córdoba, Granada, Málaga, Seville, Zaragoza, Santander, Burgos, Badalona

2024-07-17

Active, closed

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

NCT06456346Essential Thrombocythemia

DrugsBomedemstat·Hydroxyurea

Merck Sharp & Dohme LLC

Phase 3

300

Badalona, L'Hospitalet de Llobregat, Santander, Barcelona, Madrid, Marbella, Salamanca

2024-07-16

Recruiting

Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer

NCT06582628Metastatic Prostate Cancer

DrugEnzalutamide

Fundacion Oncosur

Phase 2

Badalona, Barcelona, Sabadell, Santander, Cadiz, Madrid, Málaga, Barakaldo

2024-07-05

Recruiting

Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 OUS Study)

NCT06495970Pulmonary Hypertension

Gradient Denervation Technologies

Not applicable

Badalona, Barcelona, Valencia

2024-06-26

Recruiting

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

NCT06463587Generalized Myasthenia Gravis

DrugCladribine

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 3

264

Badalona, Córdoba, Oviedo, Barcelona, Valencia

2024-06-25

Active, closed

Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

NCT06359002Relapsed / Refractory AML, Relapsed / Refractory MDS

Byondis B.V.

Phase 1

Badalona, Barcelona, Cáceres, Salamanca, Valencia

2024-06-25

Active, closed

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)

DrugZiltivekimab

Novo Nordisk A/S

Phase 3

10,000

Badalona, Málaga, El Palmar, A Coruña, Alicante, Barcelona, Lleida, Madrid

2024-06-25

Active, closed

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

NCT06356129Large B-cell Lymphoma

DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone

Celgene

Phase 3

850

A Coruña, Badalona, L'Hospitalet Del Llobregat, Barakaldo, Santa Cruz de Tenerife, Donostia / San Sebastian, Majadahonda, El Palmar, Murcia

2024-06-19

Recruiting

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

6,712

Badalona, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Málaga, Sanlúcar de Barrameda, Santiago de Compostela

2024-06-17

Recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801Crohn's Disease

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,200

Badalona, Barcelona, A Coruña, Majadahonda, Torrejón de Ardoz, Madrid, Pontevedra, Santa Cruz de Tenerife

2024-06-05

Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis

DrugsNavtemadlin·Jakavi·Ruxolitinib

Kartos Therapeutics, Inc.

Phase 3

600

Badalona, Barcelona, Cáceres, Las Palmas de Gran Canaria, Madrid, Málaga, Salamanca, Valencia

2024-06-03

Not yet open

Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler

NCT05284474Fetal Growth Retardation, Preeclampsia, Placenta Diseases

Hospital Universitari Vall d'Hebron Research Institute

Not applicable

340

A Coruña, Alicante, Badalona, Barcelona, Cadiz, Elche, Getafe, Gijón

2024-06-03

Recruiting

Immunological Characteristics of Preclinical IBD

NCT05698745Crohn Disease, Ulcerative Colitis, IBD

Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

Observational

450

Santiago de Compostela, Badalona, Manresa, Terrassa, Donostia / San Sebastian, Vigo, Gijón, Oviedo

2024-06-01

Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

DrugPegozafermin

89bio, Inc.

Phase 3

762

Almería, Badalona, Barcelona, Córdoba, Madrid, Málaga, Pontevedra, Santander

2024-05-24

Recruiting

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

NCT06133972Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

550

Santiago Compostela, Badalona, Santander, Barcelona, San Sebastian Reyes, Madrid, Valencia

2024-05-21

Recruiting

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection

Vedanta Biosciences, Inc.

Phase 3

852

Badalona, Barcelona, Terrassa, San Sebastián, Madrid, Majadahonda, Seville, A Coruña

2024-05-20

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Badalona, Ourense, León, Madrid, Salamanca, Valencia

2024-05-19

Active, closed

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

NCT05739942Newly Diagnosed and Recurrent Glioblastoma

DrugsGa-NeoB·Lu-NeoB

Novartis Pharmaceuticals

Phase 1

Granada, Badalona, L'Hospitalet de Llobregat, Madrid

2024-05-15

Active, closed

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

NCT06309966Focal Epilepsy

DrugOpakalim

Biohaven Therapeutics Ltd.

Phase 2/3

390

Badalona, L'Hospitalet de Llobregat, Pamplona, Vigo, Barcelona, Granada, Madrid, Málaga

2024-05-13

Active, closed

A Study Evaluating APG777 in Atopic Dermatitis

NCT06395948Atopic Dermatitis

DrugAPG777

Apogee Therapeutics, Inc.

Phase 2

470

Santiago de Compostela, Badalona, Las Palmas de Gran Canaria, Alicante, Barcelona, Madrid, Zaragoza

2024-04-29

Recruiting

Reduction of the Incidence of NAV in Neonatal Units (INBERNAV-Neo)

NCT07240038Pneumonia Ventilator Associated, Pneumonia Neonatal, Healthcare-associated Infections

Biobizkaia Health Research Institute

Observational

1,500

A Coruña, Santiago de Compostela, Albacete, Badalona, Barcelona, Barakaldo, Bilbao, Burgos

2024-04-26

Recruiting

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

NCT05980806Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia

DrugsMomelotinib·Pacritinib·Selinexor·Ruxolitinib

Karyopharm Therapeutics Inc

Phase 2

Badalona, El Palmar, Oviedo, Cáceres, Girona, Las Palmas de Gran Canaria, Salamanca, Valencia

2024-04-22

Active, closed

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

NCT06211764Non-Muscle Invasive Bladder Neoplasms

DrugsTAR-200·Mitomycin C·Gemcitabine

Janssen Research & Development, LLC

Phase 3

272

Badalona, Barcelona, Madrid, Málaga, Sabadell, Santander, Seville, Valencia

2024-04-09

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

NCT06268873Chronic Kidney Disease and Hypertension

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

2,554

A Coruña, Almería, Badalona, L'Hospitalet de Llobregat, Lugo, Madrid, Málaga, Palma deMallorca

2024-03-29

Active, closed

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767Bladder Cancer

DrugsIntismeran autogene·Enfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 1/2

230

Badalona, Pozuelo de Alarcón, Madrid, Barcelona, Seville

2024-03-28

Recruiting

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

NCT06093672Polycythemia Vera

DrugHydroxyurea

Italfarmaco

Phase 3

220

Badalona, Alicante, Madrid, Málaga, Valencia

2024-03-26

Recruiting

A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

NCT07699328EGFR-Mutant Non-Small Cell Lung Cancer

Voronoi, Inc

Phase 1/2

315

Badalona, L'Hospitalet de Llobregat, Madrid, Málaga

2024-03-26

Recruiting

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

NCT06236269Breast Cancer Stage IV

DrugSacituzumab Govitecan

SOLTI Breast Cancer Research Group

Phase 2

Badalona, L'Hospitalet de Llobregat, Barcelona, Granada, Madrid, Reus, Seville, Valencia

2024-03-15

Recruiting

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

NCT05904119First Progression of Glioblastoma

DrugLomustine

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3

411

Badalona, L'Hospitalet de Llobregat, Madrid

2024-03-15

Active, closed

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

NCT06220604Plaque Psoriasis

DrugsIcotrokinra·Deucravacitinib

Janssen Research & Development, LLC

Phase 3

731

Alcorcón, Badalona, Barcelona, Manises, Salamanca, Santiago de Compostela, Seville, Villajoyosa

2024-03-09

Active, closed

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

NCT06292013Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)

DrugLepodisiran

Eli Lilly and Company

Phase 3

17,300

A Coruña, Alcorcón, Badalona, Barcelona, Córdoba, Denia, El Palmar, Murcia, Ferrol

2024-03-05

Active, closed

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

NCT06241118Dermatitis Atopic

DrugsPimecrolimus·Amlitelimab·Tacrolimus

Sanofi

Phase 3

464

Badalona, Majadahonda, Seville, Alicante, Madrid

2024-02-29

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

NCT05979311HIV, HIV Infections

DrugsBictegravir·Dolutegravir·Emtricitabine·Lamivudine

ViiV Healthcare

Phase 3

307

Badalona, Barcelona, Elche Alicante, La Laguna-Tenerife, Madrid, Marbella, Palma de Mallorca, Valencia

2024-02-21

Active, closed

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

NCT06012435Carcinoma, Non-Small-Cell Lung

DrugsSigvotatug vedotin·Docetaxel

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

762

Palma, A Coruña, Barcelona, Alicante, Badalona, Castellon, Madrid, Málaga

2024-02-21

Active, closed

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer

DrugTarlatamab

Amgen

Phase 3

404

Málaga, Seville, Zaragoza, Las Palmas de Gran Canaria, Badalona, Barcelona, Santiago de Compostela, Majadahonda

2024-02-20

Active, closed

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

NCT05907096Delayed Graft Function

DrugEmpasiprubart

argenx

Phase 2

103

Badalona, Barcelona, Granada, L'Hospitalet de Llobregat, Valencia, Zaragoza

2024-02-17

Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575Multiple Myeloma

DrugsElotuzumab·Elranatamab·Carfilzomib·Pomalidomide

Pfizer

Phase 3

492

Badalona, Terrassa, Barakaldo, Barcelona, Murcia, Girona, Valencia, Madrid

2024-02-08

Recruiting

Study of Olverembatinib (HQP1351) in Patients With CML-CP

NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase

DrugsBosutinib·Olverembatinib

Ascentage Pharma Group Inc.

Phase 3

333

Badalona, Barcelona, Elche, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Murcia

2024-02-05

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744Follicular Lymphoma (FL)

DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine

Genmab

Phase 3

1,095

Badalona, L'Hospitalet de Llobregat, Santander, Pamplona, Barcelona, Cáceres, Madrid, Salamanca

2024-02-05

Active, closed

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

NCT05955508Smoldering Multiple Myeloma (SMM)

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 2

Santiago de Compostela, Granada, Palma Mallorca, Badalona, Santander, Pozuelo de Alarcón, El Palmar, Pamplona

2024-01-30

Active, closed

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06212999Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

617

Alicante, Badalona, Barcelona, Granada, Las Palmas de Gran Canaria, Madrid, Manises, Pontevedra

2024-01-30

Recruiting

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

NCT06008197Heart Failure, Acute Heart Failure

DrugsKerendia·Finerenone

Colorado Prevention Center

Phase 3

5,200

Villamartín, Zaragoza, Badalona, Sanlúcar de Barrameda, A Coruña, Santiago de Compostela, Pamplona, Barcelona

2024-01-17

Recruiting

Prospective, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Endovascular Treatment in Patients With Cerebral Aneurysms Using P64 and P48 Flow-Diverter Stents

NCT06201598Cerebral Aneurysm, Thromboembolic Disease

Hospital Universitario Central de Asturias

Observational

100

A Coruña, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Madrid, Málaga, Oviedo

2024-01-12

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma

DrugsErbitux·Cetuximab

AVEO Pharmaceuticals, Inc.

Phase 3

410

Alicante, Badalona, Barcelona, Cadiz, Madrid, Málaga, Santander, Valencia

2024-01-11

Recruiting

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

NCT07159750Migraine, Episodic Migraine, Chronic Migraine, Headache

Hospital Universitari Vall d'Hebron Research Institute

Observational

700

Badalona, Barcelona, L'Hospitalet de Llobregat, Mollet del Vallès, Viladecans, Albacete, Madrid, Zaragoza

2024-01-02

Active, closed

Endoscopic Versus Robotic Myotomy for Treatment of Achalasia

NCT06290882Achalasia Cardia

Germans Trias i Pujol Hospital

Not applicable

144

Badalona

2024-01-01

Recruiting

Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)

NCT06379945Myelodysplastic Syndromes

Instituto de Investigación Biomédica de Salamanca

Observational

300

Badalona, Barcelona, Pamplona, Salamanca

2024-01-01

Active, closed

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879Essential Thrombocythemia

DrugsAnagrelide·Bomedemstat·Busulfan·Ruxolitinib

Merck Sharp & Dohme LLC

Phase 3

340

Badalona, L'Hospitalet Del Llobregat, Barcelona, Santiago de Compostela, Madrid, Marbella, Albacete, Málaga

2023-12-31

Recruiting

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential

Orchestra BioMed, Inc

Not applicable

316

Badalona, Barcelona, Madrid, Santa Cruz de Tenerife

2023-12-27

Recruiting

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

NCT06150157Neoplasms

DrugsMomelotinib·Ruxolitinib

Janssen Research & Development, LLC

Phase 1

300

Badalona, Valencia

2023-12-20

Active, closed

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411Vitiligo

DrugUpadacitinib

AbbVie

Phase 3

614

Badalona, Getafe, Pozuelo de Alarcón, Granada, Madrid, Valencia, Zaragoza

2023-12-19

Recruiting

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

NCT05828511Multiple Myeloma

DrugLinvoseltamab

Regeneron Pharmaceuticals

Phase 1/2

149

Badalona, Pozuelo de Alarcón, Pamplona, Oviedo, Alicante, Barcelona, Madrid, Salamanca

2023-12-19

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Badalona, Barcelona, Jaén, Madrid, Valencia

2023-12-14

Recruiting

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT06091865Diffuse Large B-cell Lymphoma (DLBCL)

DrugsOdronextamab·Prednisone/Prednisolone·Adriamycin·Cytoxan

Regeneron Pharmaceuticals

Phase 3

904

Santiago de Compostela, Seville, Palma, Badalona, Sabadell, Terrassa, Santander, A Coruña

2023-12-13

Active, closed

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

DrugsGiredestrant·Abemaciclib·Ribociclib·Palbociclib

Hoffmann-La Roche

Phase 3

1,050

Badalona, Jerez de la Frontera, Pozuelo de Alarcón, EL Palmar (EL Palmar), Vigo, Barcelona, Huelva, Jaén

2023-12-11

Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

NCT06106945Multiple Myeloma

DrugsElranatamab·Pomalidomide·Dexamethasone

AstraZeneca

Phase 1/2

226

Badalona, Madrid, Pamplona, Salamanca

2023-12-05

Active, closed

A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

NCT06514807Essential Thrombocythaemia

DrugBesremi

AOP Orphan Pharmaceuticals AG

Phase 3

117

Badalona, Barcelona, Madrid, Murcia

2023-12-04

Active, closed

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

NCT05988073Multifocal Motor Neuropathy

argenx

Observational

413

Alicante, Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Oviedo, Pamplona, San Sebastián

2023-11-29

Active, closed

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

NCT06113445NonSegmental Vitiligo

DrugPovorcitinib

Incyte Corporation

Phase 3

467

Alcorcón, Badalona, Barcelona, Madrid, Manises

2023-11-29

Active, closed

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

NCT06282978Multiple Myeloma in Relapse

DrugElranatamab

PETHEMA Foundation

Phase 2

Santiago de Compostela, Palma de Mallorca, Badalona, Santander, Jerez de la Frontera, Las Palmas de Gran Canaria, El Palmar, Barcelona

2023-11-23

Active, closed

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer

DrugsPalazestrant·Exemestane·Anastrozole·Letrozole

Olema Pharmaceuticals, Inc.

Phase 3

510

Badajoz, Badalona, Manresa, Girona, León, Lleida, Madrid, Pamplona

2023-11-16

Recruiting

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

NCT05583617Multiple Myeloma

DrugsCevostamab·Iberdomide·Tocilizumab·Lenalidomide

Hoffmann-La Roche

Phase 1/2

200

Badalona, Madrid, Valencia

2023-11-14

Active, closed

Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

NCT05784012Head and Neck Squamous Cell Carcinoma

DrugsNiraparib·Dostarlimab·Cisplatin

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Phase 1/2

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia

2023-11-13

Recruiting

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

NCT06084481Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma

DrugsTelisotuzumab Adizutecan·Itraconazole·Bevacizumab

AbbVie

Phase 1

325

Badalona, Pamplona, Barcelona, Madrid, Málaga, Zaragoza

2023-11-09

Active, closed

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo

DrugRitlecitinib

Pfizer

Phase 3

1,571

Córdoba, Badalona, L'Hospitalet de Llobregat, Santiago de Compostela, Madrid, Barcelona, Valencia, Zaragoza

2023-11-08

Active, closed

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

NCT06101134Melanoma

DrugsPhesgo·Relatlimab·Opdivo·Nivolumab

Bristol-Myers Squibb

Phase 2

100

Barcelona, Cartagena, Badalona, Cantabria, San Pedro Alcántara, Málaga, Seville

2023-11-06

Active, closed

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

NCT06054555Melanoma

DrugsOpdivo·Nivolumab

Amgen

Phase 3

633

Seville, Badalona, Cáceres, El Palmar, Barcelona, Madrid, Málaga, Valencia

2023-11-02

Recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

NCT05862012Relapsed/Refractory Multiple Myeloma

Ichnos Sciences SA

Phase 1

200

Salamanca, Badalona, Barcelona, Madrid, Pamplona

2023-11-01

Active, closed

A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development

NCT06055725Spasticity as Sequela of Stroke

Ipsen

Observational

1,057

Badalona, Barcelona, Madrid, Seville, Vigo, Zaragoza

2023-11-01

Active, closed

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

NCT05985915Sjogrens Syndrome

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

612

Badalona, Sabadell, Bilbao, Santander, Vigo, A Coruña, Barcelona, Córdoba

2023-10-27

Active, closed

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

NCT05899608Non-Small Cell Lung Cancer

DrugsIvonescimab·Pembrolizumab

Summit Therapeutics

Phase 3

1,600

Badajoz, Badalona, Barcelona, Girona, Jaén, Las Palmas de Gran Canaria, Lugo, Madrid

2023-10-26

Active, closed

A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

NCT06052059Ulcerative Colitis

DrugTulisokibart

Merck Sharp & Dohme LLC

Phase 3

1,109

Badalona, Terrassa, Galdakao-Usansolo, Fuenlabrada, Madrid, Torrejón de Ardoz, Valencia

2023-10-25

Active, closed

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

NCT06025578Progressive Pulmonary Fibrosis

DrugAdmilparant

Bristol-Myers Squibb

Phase 3

1,057

Badalona, Barcelona, Santander, Santiago de Compostela, Málaga, Madrid, Majadahonda, Oviedo

2023-10-25

Active, closed

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

NCT05968326Adenocarcinoma, Pancreatic Ductal

DrugsAutogene cevumeran·MFOLFIRINOX·Tecentriq·Atezolizumab

Genentech, Inc.

Phase 2

260

Badalona, Málaga, Pamplona/iruña, Oviedo, Barcelona, Madrid

2023-10-18

Active, closed

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06045806Multiple Myeloma

DrugsIdecabtagene vicleucel·Endoxan·Fludara·Cytoxan

Celgene

Phase 3

Badalona, L'Hospitalet Del Llobregat, Barcelona, Pamplona, Madrid, Salamanca, Valencia

2023-10-16

Active, closed

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

NCT06095102Plaque Psoriasis

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

311

Badalona, Barcelona, Esplugues de Llobregat, Granada, Madrid, Manises, Seville, Valencia

2023-10-12

Active, closed

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

NCT05257083Multiple Myeloma

DrugsCilta-cel·Bortezomib·Daratumumab·Lenalidomide

Stichting European Myeloma Network

Phase 3

759

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santiago de Compostela, Seville, Valencia

2023-10-10

Active, closed

A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma

NCT05888844Cutaneous Squamous Cell Carcinoma

DrugINCB099280

Incyte Corporation

Phase 2

Badalona, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Seville

2023-10-09

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

A Coruña, Albacete, Alicante, Badalona, Barakaldo, Barcelona, Burgos, Castellon

2023-10-05

Active, closed

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

NCT05911295Urothelial Carcinoma

DrugsDisitamab Vedotin·Keytruda·Gemcitabine·Cisplatin

Seagen, a wholly owned subsidiary of Pfizer

Phase 3

412

Badalona, L'Hospitalet de Llobregat, Barakaldo, Santander, Majadahonda, Badajoz, Barcelona, L'Hospitaler de Llobregat

2023-09-22

Active, closed

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

NCT05849610High-Risk de Novo Multiple Myeloma

DrugsTalquetamab·Teclistamab·Bortezomib·Daratumumab

PETHEMA Foundation

Phase 2

Badalona, Barcelona, Madrid, Murcia, Pamplona, Salamanca, Santander, Santiago de Compostela

2023-09-21

Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)

DrugsElotuzumab·Linvoseltamab·Pomalidomide·Dexamethasone

Regeneron Pharmaceuticals

Phase 3

410

Santiago de Compostela, Vitoria-Gasteiz, Palma, Palma Mallorca, Badalona, Terrassa, Santander, León

2023-09-18

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

NCT06051617Primary Biliary Cholangitis

DrugSeladelpar

Gilead Sciences

Phase 3

402

A Coruña, Alcorcón, Badalona, Barcelona, Córdoba, Málaga, Santander, Seville

2023-09-07

Recruiting

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

NCT05365659B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma

Iksuda Therapeutics Ltd.

Phase 1

140

Badalona, Madrid, Salamanca

2023-09-05

Recruiting

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

DrugOlverembatinib

Ascentage Pharma Group Inc.

Phase 3

350

Badalona, Barcelona, Cáceres, Madrid, Santander, Seville, Valencia

2023-08-31

Active, closed

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

NCT06052267Asthma

Teva Branded Pharmaceutical Products R&D LLC

Phase 3

2,772

Badalona, Barcelona, Córdoba, Madrid, Sabadell, Santiago de Compostela, Seville, Valencia

2023-08-30

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

NCT06023589Asthma

DrugTezepelumab

AstraZeneca

Phase 3

231

Badalona, Barcelona, Esplugues de Llobregat (Barc), Madrid, Sabadell, Valencia, Villarreal

2023-08-24

Active, closed

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

NCT05909397Breast Cancer

DrugsVepdegestrant·Letrozole

Pfizer

Phase 3

Badalona, Barcelona, Jaén, Málaga, Granada, Madrid

2023-08-09

Recruiting

Coroflex® ISAR NEO PMCF Study

NCT05698732Coronary Artery Disease (CAD), Ischemic Heart Disease

Fundación EPIC

Observational

3,000

A Coruña, Badajoz, Badalona, Barakaldo, Barcelona, Cáceres, Ciudad Real, Huelva

2023-08-04

Active, closed

A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT05776472Paroxysmal Nocturnal Hemoglobinuria

DrugPegcetacoplan

Swedish Orphan Biovitrum

Observational

165

Badalona, Barakaldo, Barcelona, Bilbao, Donostia / San Sebastian, El Palmar, Huelva, Las Palmas de Gran Canaria

2023-06-26

Active, closed

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

NCT05827016Multiple Myeloma

DrugsIberdomide·Lenalidomide

Bristol-Myers Squibb

Phase 3

1,230

Barcelona, Cáceres, Las Palmas de Gran Canaria, Murcia, Oviedo, Valencia, Badalona, Madrid

2023-06-22

Recruiting

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

NCT05789082Non-Small Cell Lung Cancer

DrugsDivarasib·Pemetrexed·Cisplatin·Carboplatin

Hoffmann-La Roche

Phase 1/2

320

Badalona, Barcelona, Madrid, Seville, Valencia

2023-06-20

Active, closed

Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

NCT05673187NSCLC Stage IV, KRAS P.G12C

DrugAdagrasib

ETOP IBCSG Partners Foundation

Phase 2

A Coruña, Alicante, Badalona, Bilbao, L'Hospitalet de Llobregat, Madrid, Valencia

2023-06-12

Active, closed

Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

NCT05817942Ulcerative Colitis

DrugFilgotinib

Alfasigma S.p.A.

Observational

509

Barcelona, Badalona, Las Palmas de Gran Canaria, Palma de Mallorca, Santiago de Compostela

2023-06-12

Active, closed

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

NCT05888831Advanced Solid Tumors

DrugsOpdivo·Nivolumab

Bristol-Myers Squibb

Phase 1/2

100

Málaga, Badalona, Pamplona, Madrid

2023-06-06

Active, closed

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT05869903Obesity, Overweight, Overweight or Obesity

DrugOrforglipron

Eli Lilly and Company

Phase 3

3,127

A Coruña, Ferrol, Almería, Málaga, Seville, Badalona, Barcelona, Valladolid

2023-06-05

Recruiting

Impact of Nipple Reconstruction in Mastectomized Patients Using Cross-Linked Hyaluronic Acid Injection.

NCT07008339Breast Neoplasms, Mastectomy, Mammaplasty, Nipple Disorder

Germans Trias i Pujol Hospital

Not applicable

138

Badalona

2023-06-02

Active, closed

GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.

NCT05674422Patients With Locally Advanced Rectal Cancer

Grupo Espanol Multidisciplinario del Cancer Digestivo

Observational

120

Badalona, Terrassa, Madrid, Barcelona, Girona, Valencia, Zaragoza

2023-05-26

Active, closed

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

NCT05557591Advanced Non-Small Cell Lung Cancer

DrugsBNT116·Cemiplimab

Regeneron Pharmaceuticals

Phase 2

Badalona, Manresa, Castellon, Madrid, Málaga, Pamplona, Valencia

2023-04-21

Recruiting

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

NCT05639647Gram-negative Bacterial Infections

Pfizer

Phase 2

Badalona, Esplugues de Llobregat, Madrid, Barcelona

2023-04-18

Active, closed

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

NCT05611931Endometrial Cancer

DrugSelinexor

Karyopharm Therapeutics Inc

Phase 3

257

Donostia / San Sebastian, Zaragoza, Badalona, Barcelona, Córdoba, Girona, Granada, Madrid

2023-04-18

By invitation

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

NCT05669989Plasma Cell Myeloma

DrugsIsatuximab·Carfilzomib·Cemiplimab·Pomalidomide

Sanofi

Phase 2

Seville, Santander, Badalona, Madrid, Pamplona, Salamanca

2023-04-05

Active, closed

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

NCT05692180Asthma

DrugBenralizumab

AstraZeneca

Phase 3

Badalona, Barcelona, Benalmádena, Esplugues de Llobregat

2023-04-05

Active, closed

Evaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation

NCT05758909Aortic Valve Disease, Aortic Valve Stenosis, Heart Valve Diseases

Fundación EPIC

Observational

585

A Coruña, Alicante, Aravaca, Badalona, Barcelona, L'Hospitalet de Llobregat, Málaga, Oviedo

2023-04-04

Active, closed

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT05769777Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2

999

Badalona, Sabadell, Alicante, Córdoba, Madrid, Valencia

2023-04-03

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

NCT05774951Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

4,300

A Coruña, Albacete, Alcoy, Alicante, Alzira, Badajoz, Badalona, Barakaldo

2023-03-31

Active, closed

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

NCT05819359Parkinson's Disease

Bial R&D Investments, S.A.

Phase 2

237

Badalona, Barakaldo, Barcelona, Madrid, Seville

2023-03-31

Active, closed

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05572515Relapsed or Refractory Multiple Myeloma

DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib

Janssen Research & Development, LLC

Phase 3

614

Badalona, Jerez de la Frontera, L'Hospitalet de Llobregat, León, Madrid, Murcia, Oviedo, Palma de Mallorca

2023-03-29

Active, closed

Sequent Extended Study

NCT05788432Coronary Artery Disease, Ischemic Heart Disease

Fundación EPIC

Observational

2,040

Alava, Alicante, Badajoz, Badalona, Barakaldo, Barcelona, Cadiz, Castelló

2023-03-28

Active, closed

Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI

NCT05601973Non Small Cell Lung Cancer

DrugsLazertinib·Zirabev·Amivantamab

ETOP IBCSG Partners Foundation

Phase 2

A Coruña, Alicante, Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Madrid, Valladolid

2023-03-27

Active, closed

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

NCT05705349HIV-1 Infection

DrugsDOR/ISL·B/F/TAF

Merck Sharp & Dohme LLC

Phase 3

537

Elche, Badalona, Barcelona, L'Hospitalet de Llobregat,Barcelona, Madrid, Málaga

2023-03-08

Active, closed

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

NCT05526755Stage II-IIIB Non-small Cell Lung Carcinoma

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 2

188

Badalona, Barcelona, Bilbao, Granada, L'Hospitalet de Llobregat, Madrid, Seville, Valencia

2023-03-06

Active, closed

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

NCT05625399Melanoma

DrugsPhesgo·Relatlimab·Nivolumab

Bristol-Myers Squibb

Phase 3

579

A Coruña, Barcelona, Donostia / San Sebastian, Jaén, Madrid, Valencia, Badalona, Las Palmas de Gran Canaria

2023-03-06

Active, closed

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623Advanced Breast Cancer

DrugsVepdegestrant·Fulvestrant

Pfizer

Phase 3

624

A Coruña, Elche, Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Donostia / San Sebastian, Lleida

2023-03-03

Active, closed

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

NCT05639114Systemic Lupus Erythematosus

DrugIanalumab

Novartis Pharmaceuticals

Phase 3

436

Santiago Compostela, Elche, Badalona, Santander, Barcelona, San Sebastian Reyes, Pamplona, Vigo

2023-03-02

Active, closed

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

NCT05201066Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

DrugsSpartalizumab·Decitabine·Azacitidine·Venetoclax

Novartis Pharmaceuticals

Phase 2

Badalona, Barcelona, Madrid

2023-02-28

Recruiting

The Safety and Feasibility of the eLym™ System

NCT05747196Heart; Decompensation, Congestive

WhiteSwell, Limited

Not applicable

Barcelona, Badalona, Madrid, Majadahonda, San Carlos, Valencia, Valladolid

2023-02-28

Recruiting

A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

NCT05723198Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases

DrugBaricitinib

Eli Lilly and Company

Phase 3

595

Badalona, Barcelona, Bilbao (Bizkaia), Madrid, Valencia

2023-02-27

Active, closed

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034Ischemic Stroke; Ischemic Attack, Transient

DrugMilvexian

Janssen Research & Development, LLC

Phase 3

12,523

A Coruña, Albacete, Alicante, Badalona, Barakaldo, Barcelona, Córdoba, Girona

2023-02-15

Active, closed

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976Diffuse Large B-Cell Lymphoma

DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone

Genmab

Phase 3

900

Badalona, Barcelona, L'Hospitalet de Llobregat, Córdoba, Madrid, El Palmar, Pamplona, Valencia

2023-02-08

Recruiting

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

NCT05982093Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Premenopausal Breast Cancer

DrugsElacestrant·Tamoxifen

SOLTI Breast Cancer Research Group

Phase 2

Badalona, L'Hospitalet de Llobregat, Vilanova, El Palmar, Badajoz, Barcelona, Cáceres, Madrid

2023-02-03

Active, closed

Treatment of Functionally Non-significant Vulnerable Plaques in Patients With Multivessel ST-elevation Myocardial Infarction The VULNERABLE Trial

NCT05599061Coronary Artery Disease, Coronary Disease, Ischemic Heart Disease

Fundación EPIC

Not applicable

609

L'Hospitalet de Llobregat, A Coruña, Albacete, Alicante, Badalona, Barcelona, Cadiz, Castellon

2023-01-30

Active, closed

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

NCT05608291Melanoma

DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab

Regeneron Pharmaceuticals

Phase 3

1,564

Badalona, Santander, Barcelona, Oviedo, Granada, Lugo, Madrid, Seville

2023-01-16

Active, closed

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

NCT05527184Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer

DrugIMGN151

AbbVie

Phase 1

256

Badalona, Córdoba, Barcelona, Madrid, Valencia

2023-01-11

Active, closed

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

NCT05552976Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Carfilzomib·Dexamethasone

Bristol-Myers Squibb

Phase 3

606

Badalona, Barcelona, L'Hospitalet Del Llobregat, Madrid, Majadahonda, San Cristóbal de La Laguna, Valencia, Granada

2023-01-10

Active, closed

A Study of Daratumumab

NCT05438043Multiple Myeloma

DrugsCarfilzomib·Pomalidomide·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

213

Alcorcón, Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Pozuelo de Alarcón

2022-12-15

Recruiting

Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

NCT03994471End Stage Renal Disease

Iperboreal Pharma Srl

Phase 3

170

A Coruña, Badalona, Barcelona, Girona, Madrid, Oviedo

2022-12-14

Active, closed

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

NCT05581303Atherosclerotic Cardiovascular Disease

DrugOlpasiran

Amgen

Phase 3

7,297

Córdoba, Málaga, Seville, Zaragoza, León, Badalona, Barcelona, L'Hospitalet de Llobregat

2022-12-14

Active, closed

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

NCT05681351Severe Hypertriglyceridemia

DrugOlezarsen

Ionis Pharmaceuticals, Inc.

Phase 3

885

A Coruña, Badalona, Barcelona, Córdoba, Jaén, Madrid, Málaga, Sabadell

2022-12-13

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

NCT05633654Triple Negative Breast Cancer

DrugsXeloda·Sacituzumab Govitecan·Keytruda·Capecitabine

Gilead Sciences

Phase 3

1,514

A Coruña, Badalona, Barakaldo, Barcelona, Castellon, Cáceres, Córdoba, Donostia / San Sebastian

2022-12-12

Recruiting

Prospective Multicenter Randomized Comparative Study of the Treatment of de Novo Stenosis in Chron's Disease.

NCT04330846Crohn Disease

Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa

Not applicable

Badalona, L'Hospitalet de Llobregat, Manresa, Sabadell, Sant Joan Despí, Terrassa, Cáceres, Girona

2022-11-29

Active, closed

NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial

NCT05569811Breast Cancer

DrugsPatritumab deruxtecan·Letrozole

SOLTI Breast Cancer Research Group

Phase 2

120

Badalona, Santa Cruz de Tenerife, A Coruña, Fuenlabrada, Móstoles, Badajoz, Barcelona, Bilbao

2022-11-25

Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

NCT05652335Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis

DrugRamantamig

Janssen Research & Development, LLC

Phase 1

180

Badalona, Barcelona, Madrid, Pamplona, Salamanca

2022-11-22

Recruiting

Pharmacokinetics and Safety of Rupatadine in Participants With Renal Impairment Compared to Control Participants

NCT06708520Renal Impairment

DrugRupatadine

Noucor Health S.A.

Phase 1

Badalona, Barcelona, Madrid

2022-11-21

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

NCT05623020Multiple Myeloma

DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide

Pfizer

Phase 3

1,060

Santiago de Compostela, Badalona, L'Hospitalet Del Llobregat, Terrassa, Santander, Barcelona, Girona, Madrid

2022-11-10

Recruiting

NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

NCT05558319Newly Diagnosed Multiple Myeloma

DrugsIberdomide·Isatuximab·Bortezomib·Lenalidomide

PETHEMA Foundation

Phase 3

480

Alcalá de Henares, Pozuelo de Alarcón, Pamplona, Albacete, Badalona, Barcelona, Bilbao, Burgos

2022-11-10

Active, closed

Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer

NCT05384015Small Cell Lung Cancer Extensive Stage

DrugsLenvatinib·Etoposide·Keytruda·Carboplatin

Fundación GECP

Phase 2

Alicante, Badalona, Barcelona, Bilbao, Girona, A Coruña, Lugo, Madrid

2022-11-07

Active, closed

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

NCT05389449Paroxysmal Nocturnal Hemoglobinuria

DrugDanicopan

Alexion Pharmaceuticals, Inc.

Phase 3

Badalona, Barcelona, Majadahonda, Seville

2022-10-28

Recruiting

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

NCT05552222Multiple Myeloma

DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide

Janssen Research & Development, LLC

Phase 3

1,590

Badalona, Barcelona, Granada, Jerez de la Frontera, Madrid, Palma de Mallorca, Pozuelo de Alarcón, Salamanca

2022-10-25

Active, closed

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

NCT05565378Lung Cancer, Non-Small Cell

DrugsNelistotug·Belrestotug·Dostarlimab·Pembrolizumab

GlaxoSmithKline

Phase 2

351

Badajoz, Badalona, Barcelona, Las Palmas de Gran Canar, Madrid, Málaga, PamplonaNavarra, Valencia

2022-10-14

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Badalona, Barcelona, El Palmar, Jerez de la Frontera, León, Madrid, Málaga, Pamplona

2022-10-13

Recruiting

Long-term Safety and Efficacy of GBG Study Participants

NCT05739591Breast Cancer

GBG Forschungs GmbH

Observational

400

Córdoba, Bilbao, Santa Cruz de Tenerife, Badalona, Barcelona, Lleida, Sabadell, Cáceres

2022-10-12

Active, closed

The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events

NCT05421286HIV-1-infection, Inflammation, AIDS

Copenhagen University Hospital, Rigshospitalet

Observational

991

Badalona, Barcelona

2022-09-28

Active, closed

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

NCT05456685High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer

DrugsMIRV·Mirvetuximab Soravtansine·Carboplatin

AbbVie

Phase 2

125

A Coruña, Badalona, Córdoba, Pamplona, Badajoz, Barcelona, Lleida, Madrid

2022-09-28

Active, closed

NCT05409066Follicular Lymphoma (FL)

DrugsEpcoritamab·Lenalidomide·Rituximab

Genmab

Phase 3

549

Badalona, L'Hospitalet de Llobregat, Santander, Córdoba, Pamplona, Barcelona, Cáceres, Madrid

2022-09-20

Recruiting

Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study

NCT05562323Monkeypox

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Observational

100

Badalona, Barcelona

2022-09-14

Active, closed

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05528510Colitis, Ulcerative

DrugsGuselkumab 1·Guselkumab 2·Guselkumab 3

Janssen Research & Development, LLC

Phase 3

418

Badalona, Seville, Villajoyosa, Zaragoza

2022-09-13

Active, closed

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

NCT05531565Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

DrugLitifilimab

Biogen

Phase 2/3

450

Badalona, Valladolid, Castellon, Alcorcón, Majadahonda, A Coruña, Barcelona, Córdoba

2022-09-13

Recruiting

Asciminib Roll-over Study

NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib

Novartis Pharmaceuticals

Phase 4

347

Santiago Compostela, Badalona, L'Hospitalet de Llobregat, Bilbao, Santa Cruz, Barcelona, Madrid, Seville

2022-08-30

Active, closed

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05361395Extensive Stage Small Cell Lung Cancer

DrugsTarlatamab·Tecentriq·Etoposide·Atezolizumab

Amgen

Phase 1

184

Badalona, Barcelona, Madrid

2022-08-24

Active, closed

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2/3

1,856

Badalona, Bilbao, Las Palmas de Gran Canaria, Pamplona, Pontevedra, Vigo, Seville, Burjassot

2022-08-22

Recruiting

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

NCT05137054Multiple Myeloma

DrugsNirogacestat·Cevostamab·Fianlimab·Linvoseltamab

Regeneron Pharmaceuticals

Phase 1

317

Santiago de Compostela, Badalona, Santander, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid, Salamanca

2022-08-17

Recruiting

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV

DrugsAbraxane·Nab-paclitaxel·Gemcitabine

Panbela Therapeutics, Inc.

Phase 2/3

600

Badalona, Santander, Jaén, Barcelona, Madrid, El Palmar, Pamplona, Barakaldo

2022-08-08

Active, closed

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

NCT05261399Carcinoma, Non-Small-Cell Lung

DrugsSavolitinib·Tagrisso·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

341

Badajoz, Badalona, Barcelona, Córdoba, Girona, Madrid, Majadahonda, Málaga

2022-08-03

Recruiting

A Systemic Screening for TB Disease in High-risk Groups in Barcelona

NCT06706596Tuberculosis, Tuberculosis, Pulmonary

Fundació Institut Germans Trias i Pujol

Observational

3,000

Badalona

2022-07-22

Active, closed

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

NCT05352672Melanoma

DrugsFianlimab·Cemiplimab·Keytruda·Pembrolizumab

Regeneron Pharmaceuticals

Phase 3

1,546

Córdoba, Badalona, Barcelona, Donostia / San Sebastian, El Palmar, Oviedo, A Coruña, Girona

2022-07-14

Recruiting

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

NCT05203172Solid Tumors

DrugsVemurafenib·Binimetinib·Encorafenib·Zirabev

Pfizer

Phase 4

210

A Coruña, Badalona, Barcelona, Santander, Lleida, Majadahonda, Madrid, Málaga

2022-07-05

Active, closed

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

NCT05267613Erosive Esophagitis

DrugNexium

AstraZeneca

Phase 3

Badalona, Santiago de Compostela, Seville

2022-07-01

Active, closed

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

NCT05257408Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms

DrugsNab-paclitaxel /m^2·Relacorilant

Corcept Therapeutics

Phase 3

381

Badalona, San Sebastián, Valencia

2022-06-29

Active, closed

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

NCT05405166Plasma Cell Myeloma Recurrent

DrugsParacetamol / Acetaminophen·Montelukast·Diphenhydramine·Isatuximab

Sanofi

Phase 3

531

Murcia, Badalona, Santander, Pamplona, Madrid, Salamanca

2022-06-23

Recruiting

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

NCT05142189Non-Small Cell Lung Cancer

DrugsBNT116·Gotistobart·Cemiplimab·Osimertinib

BioNTech SE

Phase 1

320

Badalona, Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2022-06-17

Active, closed

Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment

NCT05382052Non Small Cell Lung Cancer Stage III, Neoadjuvant Treatment

Fundación GECP

Observational

100

A Coruña, Alicante, Badalona, Barcelona, Bilbao, Córdoba, Girona, Pamplona

2022-06-17

Active, closed

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720Non-Hodgkin Lymphoma

DrugsGolcadomide·Epcoritamab·Polatuzumab Vedotin·Doxorubicin Hydrochloride

Genmab

Phase 2

264

Badalona, L'Hospitalet de Llobregat, Pamplona, Barcelona, Madrid, Salamanca, Seville, Valencia

2022-06-14

Recruiting

Spanish Academy of Dermatology and Venereology (AEDV) Melanoma Registry

NCT05673681Melanoma

Fundación Academia Española de Dermatología

Observational

7,000

Badalona, A Coruña, Barcelona, Córdoba, Las Palmas, León, Madrid, Oviedo

2022-06-01

Recruiting

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

NCT05076175Colitis, Ulcerative

DrugOzanimod

Bristol-Myers Squibb

Phase 2/3

120

Badalona, Esplugues de Llobregat, Madrid

2022-05-30

Active, closed

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

NCT05186974Non-small Cell Lung Cancer

DrugsSacituzumab Govitecan·Paraplatin·Keytruda·Cisplatin

Gilead Sciences

Phase 2

193

A Coruña, Badalona, Barcelona, Madrid, Majadahonda, Pamplona, Rincón de la Victoria, Santiago de Compostela

2022-05-30

Active, closed

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

NCT05338775Relapsed/ Refractory Multiple Myeloma

DrugsTalquetamab·Teclistamab

Janssen Research & Development, LLC

Phase 1

Badalona, Madrid, Pamplona, Salamanca

2022-05-25

Recruiting

Endoscopic Ultrasound-Guided Gastroenterostomy Nationwide: Prospective Registry.

NCT05128604Endoscopic Surgical Procedure, Safety, Training

Hospital Universitari de Bellvitge

Observational

Badalona, L'Hospitalet de Llobregat, Terrassa, Barcelona, Girona

2022-05-23

Active, closed

A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

NCT05353257Limited-Stage Small Cell Lung Cancer

DrugsCarboplatin/cisplatin-etoposide·Serplulimab

Shanghai Henlius Biotech

Phase 3

511

Badajoz, Badalona, Barcelona, Córdoba, Madrid, Seville, Valdecilla, Valencia

2022-05-17

Active, closed

Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer

NCT05296746Breast Cancer Stage II

DrugRibociclib

SOLTI Breast Cancer Research Group

Phase 2

1,100

Palma de Mallorca, Badalona, L'Hospitalet de Llobregat, Barcelona, Granada, León, Madrid, Salamanca

2022-05-03

Active, closed

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

NCT05270044Melanoma

Pierre Fabre Medicament

Phase 3

815

Badalona, L'Hospitalet de Llobregat, El Palmar, Barcelona, Córdoba, Madrid, Málaga, Valencia

2022-05-02

Recruiting

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

NCT04916613Prostate Cancer Metastatic

DrugDarolutamide

UNICANCER

Phase 3

300

Badalona, Barcelona, Girona, Madrid, Manresa, Valencia

2022-04-19

Active, closed

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

NCT05201547Endometrial Cancer

DrugsCarboplatin/Paclitaxel·Dostarlimab

ARCAGY/ GINECO GROUP

Phase 3

260

Elche, Badalona, Córdoba, León, Palma, Palma de Mallorca, Santiago de Compostela, Valencia

2022-04-15

Active, closed

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416Multiple Myeloma

DrugsElranatamab·Lenalidomide

Pfizer

Phase 3

854

Santiago de Compostela, Barcelona, L'Hospitalet Del Llobregat, Terrassa, Badalona, Salamanca, Pozuelo de Alarcón, Madrid

2022-03-25

Active, closed

Remote Optimization, Adjustment and Measurement for Deep Brain Stimulation

NCT05269862Parkinson Disease

Abbott Medical Devices

Not applicable

100

Badalona, Madrid, Seville

2022-03-24

Recruiting

Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

NCT05398094Non-small Cell Lung Cancer Stage III, KRAS P.G12C

DrugSotorasib

Fundación GECP

Phase 2

Alicante, Badalona, Barcelona, Bilbao, Girona, Granada, Jaén, A Coruña

2022-03-21

Active, closed

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

DrugsRuxience·Truxima·Zanubrutinib·Obinutuzumab

BeOne Medicines

Phase 3

799

Badalona, Burgos, Cadiz, Granada, L'Hospitalet de Llobregat, León, Madrid, Majadahonda

2022-03-10

Active, closed

A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

NCT05250973Amyloidosis

DrugsBortezomib·Daratumumab·Dexamethasone·Cyclophosphamide

Janssen Research & Development, LLC

Phase 2

151

Badalona, Barcelona, Madrid, Pamplona, Salamanca

2022-03-01

Recruiting

AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM

NCT06378632Heart Failure

Cordio Medical

Observational

500

Badalona

2022-02-11

Active, closed

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma

DrugsEvorpacept·Ramucirumab·Herceptin·Taxol

ALX Oncology Inc.

Phase 2/3

127

Alicante, Badalona, Barcelona, Córdoba, Lugo, Madrid, Santander, Zaragoza

2022-01-15

Recruiting

National GMA Post-market Clinical Follow-up Study (GRACE)

NCT05636709Crohn Disease, Ulcerative Colitis

Adacyte Therapeutics SL

Observational

350

Albacete, Alicante, Badalona, Barcelona, Galdakao, Castellon, Cadiz, Córdoba

2022-01-11

Active, closed

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT04819100Carcinoma, Non-Small-Cell Lung

DrugSelpercatinib

Eli Lilly and Company

Phase 3

152

Santiago de Compostela, Cadiz, Córdoba, Badalona, Barcelona, L'Hospitalet Del Llobregat, Mataró, León

2021-12-20

Active, closed

Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide

NCT05060627Relapsed Multiple Myeloma

DrugsBelantamab mafodotin·Carfilzomib·Dexamethasone

PETHEMA Foundation

Phase 1/2

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Oviedo, Palma de Mallorca, Pamplona

2021-12-20

Recruiting

A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

NCT05037760Myelofibrosis

DrugsElritercept·Ruxolitinib

Takeda

Phase 2

135

Badalona, Barcelona, Madrid, Salamanca, Valencia, Zaragoza

2021-12-16

Recruiting

Pathological Response After Neoadjuvant Treatment on NSCLC

NCT05167487Stage IIIA Non-small Cell Lung Cancer

DrugsParaplatin·Cisplatin·Carboplatin

Fundación GECP

Observational

150

A Coruña, Alicante, Badalona, Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda

2021-12-13

Active, closed

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

NCT04999969Locally Advanced or Metastatic Solid Tumours

DrugsAZD0171·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 2

126

Badalona, Barcelona, Madrid, Majadahonda, Pamplona

2021-12-10

Active, closed

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

NCT03496883Intracerebral Hemorrhage

DrugRecombinant Factor VIIa

Joseph Broderick, MD

Phase 3

860

Badalona, Horta, L'Hospitalet de Llobregat, Barcelona, Girona, Lleida

2021-12-03

Active, closed

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

NCT05152147Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

DrugsZanidatamab·Herceptin·Trastuzumab·Adrucil

Jazz Pharmaceuticals

Phase 3

920

Sabadell, Pamplona, Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Málaga

2021-12-02

Active, closed

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

NCT04924608Neurofibromatosis 1, Plexiform Neurofibroma (PN)

DrugSelumetinib

AstraZeneca

Phase 3

145

Badalona, Madrid

2021-11-19

Active, closed

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases

NCT05012254Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer

DrugsYervoy·Paraplatin·Taxol·Ipilimumab

Fundación GECP

Phase 2

Badalona, Barcelona, L'Hospitalet de Llobregat, Castellon, Las Palmas de Gran Canaria, Jaén, A Coruña, León

2021-11-18

Active, closed

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05089734Non-Small Cell Lung Cancer

DrugsSacituzumab Govitecan·Docetaxel

Gilead Sciences

Phase 3

603

A Coruña, Badalona, Barakaldo, Barcelona, Cáceres, Girona, Madrid, Málaga

2021-11-17

Active, closed

A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

NCT05081557Atopic Dermatitis

AbbVie

Observational

873

Badalona, Barcelona, L'Hospitalet de Llobregat, Terrassa, Granada, Huelva, Jaén, Logroño

2021-11-17

Recruiting

Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)

NCT05065216Acute Stroke, Ischemic Stroke, Stroke

DiaMedica Therapeutics Inc

Phase 2/3

728

A Coruña, Badalona, Barcelona, Santiago de Compostela

2021-11-07

Active, closed

Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

NCT04994717Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

DrugBlinatumomab

Amgen

Phase 3

303

Córdoba, Seville, Santander, Salamanca, Badalona, Barcelona, L'Hospitalet de Llobregat, Valencia

2021-11-02

Active, closed

Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

NCT05181592Myelodysplastic Syndromes

DrugsReblozyl·Luspatercept

GWT-TUD GmbH

Phase 3

Badalona, Barcelona, Madrid, Oviedo, Salamanca, Valencia

2021-10-27

Active, closed

Post Market Clinical Follow-Up Study in Patients Treated With the On-X Ascending Aortic Prosthesis (AAP)

NCT05082454Aortic Valve Disease

JOTEC GmbH

Observational

108

Badalona, Barcelona

2021-10-20

Active, closed

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

NCT04958239Neoplasms

DrugsEzabenlimab·Pembrolizumab

Boehringer Ingelheim

Phase 1

151

Badalona, Barcelona, Madrid, Pamplona

2021-10-18

Active, closed

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab

AbbVie

Phase 1

520

Santiago de Compostela, Badalona, Alcorcón, Pamplona, Barcelona, Jaén, Madrid, Seville

2021-10-13

Recruiting

Spanish Registry of Patients With IgM Monoclonal Gammopathies

NCT05093153Waldenstrom Macroglobulinemia

Fundación Española de Hematología y Hemoterapía

Observational

1,000

Mérida, Palma, Palma de Mallorca, Badalona, Barcelona, Manresa, Sabadell, Córdoba

2021-10-01

Active, closed

Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)

NCT04776252HIV-1 Infection

DrugDOR/ISL

Merck Sharp & Dohme LLC

Phase 3

2,000

Elche, Badalona, Barcelona, Madrid

2021-09-15

Active, closed

Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

NCT05063786Advanced Breast Cancer

DrugsAlpelisib·Herceptin·Eribulin·Vinorelbine

Spanish Breast Cancer Research Group

Phase 3

A Coruña, Albacete, Alicante, Badajoz, Badalona, Barcelona, Bilbao, Cadiz

2021-09-14

Recruiting

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer

DrugsKeytruda·Pembrolizumab

Medicenna Therapeutics, Inc.

Phase 1/2

115

Badalona, Barcelona, Madrid, Oviedo, Torrejón

2021-08-27

Active, closed

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

NCT04961996Early Breast Cancer

DrugGiredestrant

Hoffmann-La Roche

Phase 3

4,170

Elche, Palma de Mallorca, Badalona, Manresa, Sabadell, Santiago de Compostela, Jerez de la Frontera, Castellon de LA Plana/castello de LA Plana

2021-08-27

Active, closed

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728NASH - Nonalcoholic Steatohepatitis

Inventiva Pharma

Phase 3

1,000

Almería, Badalona, Palma de Mallorca, Barcelona, Sabadell, León, Madrid, Majadahonda

2021-08-19

Active, closed

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

NCT04976634Neoplasm Malignant

DrugsBelzutifan·Lenvatinib·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 2

730

Badalona, Santiago de Compostela, Madrid, Oviedo, Barcelona

2021-08-18

Recruiting

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy

NCT04629833Steroid-refractory Acute Graft-versus-host Disease

DrugMC0518

medac GmbH

Phase 3

210

Badalona, Barcelona, Madrid, Málaga, Valencia

2021-08-16

By invitation

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

NCT04957719Acute Myocardial Infarction

Viatris Innovation GmbH

Phase 3

25,000

Almería, Badalona, Barcelona, Boadilla del Monte, Córdoba, El Palmar, Fuencarral-El Pardo, Huelva

2021-08-14

Active, closed

Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

NCT04733118Early Breast Cancer

MedSIR

Phase 2

393

L'Hospitalet de Llobregat, Córdoba, Reus, A Coruña, Alicante, Badalona, Barcelona, Bilbao

2021-08-05

Active, closed

Pulmonary Embolism International THrOmbolysis Study-3

NCT04430569Pulmonary Embolism

DrugAlteplase

Assistance Publique - Hôpitaux de Paris

Phase 3

800

Badalona, Barcelona, Cartagena, Galdakao, Madrid, Seville, Valencia

2021-08-04

Recruiting

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

NCT04939610Solid Tumor

Drug177Lu-FAP-2286

Novartis Pharmaceuticals

Phase 1/2

222

A Coruña, Badalona, Madrid

2021-07-30

Recruiting

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

NCT04803994Hepatocellular Carcinoma

DrugsTecentriq·Avastin·Atezolizumab·Bevacizumab

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 3

434

Alicante, Badajoz, Badalona, Barcelona, Cadiz, Jaén, Madrid, Málaga

2021-07-06

Active, closed

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Abemaciclib·Ribociclib

AstraZeneca

Phase 3

315

A Coruña, Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia, Sant Joan Despí

2021-06-30

Active, closed

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958Advanced Colorectal Cancer, Metastatic Colorectal Cancer

DrugsAdagrasib·MFOLFOX6·Erbitux·Folfox

Mirati Therapeutics Inc.

Phase 3

461

A Coruña, Badalona, Barcelona, Córdoba, LHospitalet de Llobregat, Madrid, Pamplona, Sabadell

2021-06-24

Recruiting

ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer

NCT04889924Breast Cancer, Chemotherapy, Sentinel Lymph Node, Axillary Lymph Nodes Dissection

Hospital Universitari de Bellvitge

Not applicable

820

Badalona, Calella, Granollers, L'Hospitalet de Llobregat, Manresa, Mataró, Sant Cugat del Vallès, Terrassa

2021-06-11

Recruiting

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer

DrugsImzokitug·Pumitamig·Docetaxel·Nivolumab

Bristol-Myers Squibb

Phase 1/2

1,109

Málaga, Badalona, Barcelona, Madrid, Pamplona

2021-05-27

Active, closed

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

NCT04762069Glioblastoma Multiforme, Adult

DrugsCCNU·Lomustine

CNS Pharmaceuticals, Inc.

Phase 2

252

Badalona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville

2021-05-18

Active, closed

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

NCT04821622Prostate Cancer

DrugsTalazoparib·Enzalutamide

Pfizer

Phase 3

599

Elche, Badalona, L'Hospitalet de Llobregat, Manresa, Lugo, Majadahonda, Pamplona, Oviedo

2021-05-12

Active, closed

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

NCT04824092Diffuse Large B-cell Lymphoma

DrugsTafasitamab·Vincristine·Doxorubicin·Prednisone

Incyte Corporation

Phase 3

899

Badalona, Barcelona, Girona, Jerez de la Frontera, Lugo, Madrid, Pamplona, Salamanca

2021-05-11

Active, closed

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

NCT04675333Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma

DrugsEvorpacept·Cisplatin/Carboplatin·Fluorouracil·Keytruda

ALX Oncology Inc.

Phase 2

172

Barcelona, Badalona, L'Hospitalet de Llobregat, Leganés, Madrid, Málaga, Pamplona

2021-05-10

Active, closed

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

NCT04873362Breast Cancer

DrugsTrastuzumab emtansine·Herceptin·Tecentriq·Trastuzumab

Hoffmann-La Roche

Phase 3

1,188

Elche, Badalona, Sabadell, Jerez de la Frontera, Vigo, San Cristóbal de La Laguna, Bilbao, Granada

2021-05-04

Recruiting

Fast Track Therapeutic Model in Acute Complicated Appendicitis in Pediatrics

NCT05761080Laparoscopic Appendectomy, Complicated Appendicitis, Periappendicular Abscess

DrugMaximum

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Phase 4

772

Barcelona, Córdoba, Lleida, Madrid, Seville, Badalona, Esplugues de Llobregat, Girona

2021-04-22

Active, closed

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124Bladder Cancer

DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

808

Badalona, Manresa, Girona, Santiago de Compostela, Las Palmas de Gran Canaria, Oviedo, Valencia, Barcelona

2021-04-21

Active, closed

ANGiographic Evaluation of Left Main Coronary Artery INtErvention

NCT04604197Coronary Occlusion, Left Main Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease

Fundación EPIC

Not applicable

400

Badalona, Barakaldo, Donostia / San Sebastian, Málaga, Galdakao, A Coruña, Albacete, Alicante

2021-04-16

Active, closed

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052Follicular Lymphoma, Marginal Zone Lymphoma

DrugsTafasitamab·Lenalidomide·Rituximab

Incyte Corporation

Phase 3

654

A Coruña, Alicante, Badalona, Barcelona, Burgos, Gijón, L'Hospitalet de Llobregat, Madrid

2021-04-15

Active, closed

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

NCT04576156Myelofibrosis

DrugImetelstat Sodium

Geron Corporation

Phase 3

327

Alicante, Badalona, Las Palmas de Gran Canaria, Cáceres, Granada, Madrid, Málaga, Zaragoza

2021-04-12

Active, closed

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis

DrugsPelabresib·Ruxolitinib

Novartis Pharmaceuticals

Phase 3

430

Oviedo, Badalona, Barcelona, Cáceres, Las Palmas de Gran Canaria, Madrid, Murcia, Salamanca

2021-04-09

Active, closed

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

NCT04817007Myelofibrosis

DrugsBMS-986158·Fedratinib·Ruxolitinib

Bristol-Myers Squibb

Phase 1/2

216

Badalona, Santander, Madrid, Salamanca, Valencia

2021-03-22

Recruiting

DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.

NCT07717437Liver Cancer, Liver Metastases

Maastricht University Medical Center

Observational

350

Badalona, Barcelona

2021-03-16

Active, closed

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

NCT04562389Myelofibrosis

DrugsSelinexor·Ruxolitinib

Karyopharm Therapeutics Inc

Phase 3

353

Cáceres, Oviedo, Zaragoza, Badalona, Barcelona, Girona, Las Palmas de Gran Canaria, Lugo

2021-03-11

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

NCT04686305Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Durvalumab

AstraZeneca

Phase 1

304

Badalona, Madrid, Seville, Valencia

2021-03-09

Active, closed

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

NCT04486378Colorectal Cancer Stage II, Colorectal Cancer Stage III

DrugAutogene cevumeran

BioNTech SE

Phase 2

327

A Coruña, Ávila, Badalona, Barcelona, Córdoba, Madrid, Majadahonda, Málaga

2021-03-08

Recruiting

sFlt1/PlGF and Planned Delivery to Prevent Preeclampsia at Term.

NCT04766866Preeclampsia, Intrauterine Growth Restriction, Maternal Hypertension, Neonatal Outcome

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Not applicable

9,132

Badalona, Las Palmas de Gran Canaria, El Palmar, Barcelona, Madrid, Palma de Mallorca, Valencia, Zaragoza

2021-03-02

Active, closed

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

NCT04608318Chronic Lymphoid Leukemia

DrugsVenclyxto·Ibrutinib·Obinutuzumab·Venetoclax

German CLL Study Group

Phase 3

897

Badalona, Barcelona, Madrid, Málaga, Oviedo, Salamanca, Santander, Seville

2021-03-01

Active, closed

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer

DrugsAdagrasib·Taxotere·Docetaxel

Mirati Therapeutics Inc.

Phase 3

453

Pamplona, A Coruña, Alicante, Badalona, Barakaldo, Barcelona, Córdoba, Girona

2021-02-23

Active, closed

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm

DrugRuxolitinib

Incyte Corporation

Phase 1

140

Badalona, Las Palmas de Gran Canaria, Madrid, Murcia, Salamanca

2021-02-23

Active, closed

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

DrugPatritumab deruxtecan

Daiichi Sankyo

Phase 2

277

Seville, Badalona, Majadahonda, Barcelona, Madrid, Málaga, Zaragoza

2021-02-02

Active, closed

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04612751Advanced or Metastatic NSCLC

DrugsSabestomig·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 1

155

A Coruña, Badalona, Barcelona, Madrid, Seville

2021-02-02

Recruiting

First-In-Human Clinical Study for Treatment of Severe Mitral Valve INsufficiency With Epygon™ TRanscatheter Mitral VAlve System

NCT04775108Mitral Valve Regurgitation

Epygon

Not applicable

Badalona, Barcelona, Madrid, Murcia, Seville

2021-02-01

Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04634552Hematological Malignancies

DrugTalquetamab

Janssen Research & Development, LLC

Phase 2

510

Badalona, Barcelona, Madrid, Murcia, Pamplona, Pozuelo de Alarcón, Salamanca, Santander

2021-02-01

Active, closed

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659Sickle Cell Disease

DrugEtavopivat

Forma Therapeutics, Inc.

Phase 3

450

A Coruña, Badalona, Barakaldo, Barcelona, Madrid, Seville

2021-01-29

Recruiting

Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.

NCT04735198Midgut Carcinoid Tumor, Biliary Stones

Hospital Universitari de Bellvitge

Not applicable

100

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid

2021-01-20

Active, closed

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

NCT04657991Melanoma

DrugsBinimetinib·Encorafenib·Keytruda·Pembrolizumab

Pfizer

Phase 3

257

Badalona, Santander, Majadahonda, El Palmar, A Coruña, Barcelona, Córdoba, Jaén

2021-01-15

Active, closed

New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy

NCT04564157Non-Small Cell Lung Cancer, Adjuvant Chemotherapy

DrugsParaplatin·Taxol·Opdivo·Nivolumab

Fundación GECP

Phase 3

210

Alicante, Badalona, Barcelona, L'Hospitalet de Llobregat, Bilbao, Cáceres, El Palmar, Girona

2021-01-13

Active, closed

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

NCT04628494Diffuse Large B-cell Lymphoma

DrugEpcoritamab

Genmab

Phase 3

483

Badalona, Barcelona, Cadiz, Cáceres, Córdoba, Lleida, Madrid, Salamanca

2021-01-13

Active, closed

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

NCT04521231B Cell Precursor Acute Lymphoblastic Leukemia

DrugBlinatumomab

Amgen

Phase 1/2

181

Seville, Santander, Salamanca, Badalona, Barcelona, Esplugues de Llobregat, L'Hospitalet de Llobregat, Pamplona

2021-01-04

Recruiting

Development of a Novel Strategy to Analyze the Effect on Gait Using Transcutaneous Spinal Current Stimulation in Incomplete Spinal Cord Injured Patients

NCT07289191Spinal Cord Injuries, Non Invasive Spinal Stimulation, Gait Disorders, Neurologic, Motor Function; Retardation

Institut Guttmann

Not applicable

Badalona

2021-01-01

Active, closed

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

NCT04640623Urinary Bladder Neoplasms

DrugsTAR-200·Cetrelimab

Janssen Research & Development, LLC

Phase 2

220

A Coruña, Badalona, Barcelona, Cadiz, Granada, Jerez de la Frontera, Madrid, Málaga

2020-12-18

Active, closed

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04586426Multiple Myeloma

DrugsTalquetamab·Teclistamab

Janssen Research & Development, LLC

Phase 1/2

228

Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Salamanca, Santander

2020-12-15

Active, closed

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

NCT04655976Lung Cancer, Non-Small Cell

DrugsCobolimab·Dostarlimab·Docetaxel

GlaxoSmithKline

Phase 2/3

758

A Coruña, Badalona, Barcelona, Burgos, Córdoba, Las Palmas de Gran Canar, Madrid, Málaga

2020-12-08

Active, closed

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

NCT04658862Urinary Bladder Neoplasms

DrugsTAR-200·Cetrelimab·Gemcitabine·Cisplatin

Janssen Research & Development, LLC

Phase 3

518

A Coruña, Badalona, Barcelona, Granada, Jerez de la Frontera, Madrid, Sabadell, Santander

2020-12-07

Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

DrugsAdagrasib·Pembrolizumab

Mirati Therapeutics Inc.

Phase 2/3

626

Pamplona, A Coruña, Badalona, Barcelona, Bilbao, Burgos, Jerez de la Frontera, Las Palmas de Gran Canaria

2020-12-02

Active, closed

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

NCT04597125Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Bayer

Phase 4

654

Santiago de Compostela, Palma de Mallorca, Badalona, Castellon, Majadahonda, Oviedo, A Coruña, Barcelona

2020-11-09

Active, closed

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

NCT04595565HER2-negative Breast Cancer, Triple Negative Breast Cancer

DrugsXeloda·Sacituzumab Govitecan·Paraplatin·Capecitabine

GBG Forschungs GmbH

Phase 3

1,332

Barakaldo, A Coruña, Albacete, Alcorcón, Alcoy, Alicante, Badalona, Barcelona

2020-10-28

Active, closed

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

NCT04446117Metastatic Prostate Cancer, Prostate Adenocarcinoma

DrugsZytiga·Xtandi·Abiraterone·Abiraterone acetate

Exelixis

Phase 3

575

Elche, Palma de Mallorca, Manresa, Santiago de Compostela, Alcorcón, Oviedo, Badalona, Barcelona

2020-10-19

Active, closed

Myasthenia Gravis Inebilizumab Trial

NCT04524273Myasthenia Gravis

DrugInebilizumab

Amgen

Phase 3

238

Badalona, Barcelona, Córdoba

2020-10-15

Active, closed

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

NCT04538664Carcinoma, Non-Small-Cell Lung

DrugsAmivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

308

A Coruña, Badalona, Barcelona, Burgos, Madrid, Majadahonda, Málaga, Pamplona

2020-10-13

Active, closed

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

NCT04529772Diffuse Large B-Cell Lymphoma

DrugsAcalabrutinib·Vincristine·Doxorubicin·Prednisone

Acerta Pharma BV

Phase 3

611

Alcalá de Henares, Badalona, Barcelona, Gijón, L'Hospitalet de Llobregat, Madrid, Palma, Pamplona

2020-10-08

Active, closed

A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

NCT04434092Paroxysmal Nocturnal Hemoglobinuria

DrugsCrovalimab·Eculizumab

Hoffmann-La Roche

Phase 3

210

Bilbao, Badalona, Las Palmas de Gran Canaria, Barcelona, Cáceres, Madrid, Salamanca

2020-10-08

Active, closed

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT04524611Crohn's Disease (CD)

DrugsSkyrizi·Risankizumab·Ustekinumab

AbbVie

Phase 3

527

Ferrol, Santiago de Compostela, Badalona, L'Hospitalet de Llobregat, Fuenlabrada, Majadahonda, Oviedo, Alicante

2020-09-30

Active, closed

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

NCT04432584Paroxysmal Nocturnal Hemoglobinuria

DrugsCrovalimab·Eculizumab

Hoffmann-La Roche

Phase 3

190

Badalona, Santiago de Compostela, Asturias, Bilbao, Barcelona, Madrid, Málaga, Salamanca

2020-09-30

Active, closed

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04487080Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Osimertinib

Janssen Research & Development, LLC

Phase 3

1,074

A Coruña, Badalona, Barcelona, Burgos, Girona, Madrid, Majadahonda, Málaga

2020-09-30

Active, closed

Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)

NCT04483739Multiple Myeloma

European Myeloma Network B.V.

Phase 3

302

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander

2020-09-25

Active, closed

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

NCT04280718Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

DrugEfgartigimod PH20

argenx

Phase 2

229

Badalona, Barcelona, Madrid

2020-09-18

Active, closed

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04557098Hematological Malignancies

DrugTeclistamab

Janssen Research & Development, LLC

Phase 2

194

Badalona, Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander

2020-09-17

Active, closed

Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

NCT04401748Myelodysplastic Syndrome (MDS)

DrugsVenclexta·Azacitidine·Venetoclax

AbbVie

Phase 3

531

Badalona, Córdoba, Pozuelo de Alarcón, Barcelona, Madrid, Salamanca, Seville, Valencia

2020-09-10

Active, closed

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT04442022Relapsed/Refractory Diffuse Large B-cell Lymphoma

DrugsSelinexor·Rituximab·Dexamethasone·Gemcitabine

Karyopharm Therapeutics Inc

Phase 2/3

501

Badalona, Barcelona, Madrid, Seville

2020-09-03

Active, closed

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

NCT04468984Myelofibrosis (MF)

DrugsNavitoclax·Ruxolitinib

AbbVie

Phase 3

330

A Coruña, Santiago de Compostela, Badalona, Las Palmas de Gran Canaria, Oviedo, Barcelona, Granada, Madrid

2020-08-31

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

NCT04300556Solid Tumor

DrugsPrednisolone·Lenvatinib·Prednisone·Dexamethasone

Eisai Inc.

Phase 1/2

182

Badalona, Barcelona, Madrid, Toledo, Valencia

2020-08-06

Active, closed

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NCT04421963Ovarian Cancer, Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

185

Badalona, Barcelona, Córdoba, Donostia / San Sebastian, Granada, Madrid, Pamplona, Valencia

2020-08-04

Active, closed

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

NCT04509700B-Cell Malignancies

DrugsItacitinib·Parsaclisib·Ibrutinib·Ruxolitinib

Incyte Corporation

Phase 2

112

Alicante, Badalona, Barcelona, Boadilla del Monte, L'Hospitalet de Llobregat, Madrid, Pozuelo de Alarcón, Salamanca

2020-08-03

Active, closed

A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

NCT04181827Multiple Myeloma

DrugsCilta-cel·Pomalidomide·Bortezomib·Daratumumab

Janssen Research & Development, LLC

Phase 3

419

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville

2020-06-12

Active, closed

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

NCT07084896Multiple Myeloma

DrugsNirogacestat·Belantamab mafodotin

GlaxoSmithKline

Phase 1/2

106

Badalona, Madrid, Pozuelo de AlarcOn Madr

2020-06-08

Recruiting

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

NCT04256317Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia

DrugsVenclexta·Azacitidine·Venetoclax

Taiho Oncology, Inc.

Phase 2/3

316

Badalona, L'Hospitalet de Llobregat, Pamplona, Oviedo, Barcelona, Cáceres, Girona, Granada

2020-05-21

Active, closed

Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients

NCT04223596Lung Cancer, NSCLC, NSCLC Stage IIIB, NSCLC Stage IV

DrugBrigatinib

Fundación GECP

Phase 2

A Coruña, Alicante, Málaga, Palma de Mallorca, Badalona, L'Hospitalet de Llobregat, Barcelona, Las Palmas de Gran Canaria

2020-05-04

Active, closed

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689Papillomavirus Infections

DrugNonavalent HPV vaccine

Merck Sharp & Dohme LLC

Phase 3

6,033

Badalona, Centelles, L'Hospitalet de Llobregat

2020-02-27

Active, closed

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

NCT04194944Non-Small Cell Lung Cancer

DrugsSelpercatinib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

261

Palma de Mallorca, Badalona, Santiago de Compostela, Las Palmas de Gran Canaria, Majadahonda, Pamplona, Alicante, Barcelona

2020-02-17

Active, closed

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

NCT04191499Breast Cancer

DrugsInavolisib·Palbociclib·Fulvestrant

Hoffmann-La Roche

Phase 2/3

325

Badalona, Pamplona, San Cristóbal de La Laguna, Barcelona, Jaén, Madrid, Seville, Valencia

2020-01-29

Active, closed

A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer

NCT04165317Non-muscle Invasive Bladder Cancer

DrugsSasanlimab·Bacillus Calmette-Guerin

Pfizer

Phase 3

1,068

Badalona, Granollers, L'Hospitalet de Llobregat, Majadahonda, Pamplona, Reus, A Coruña, Barcelona

2019-12-30

Active, closed

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

NCT04091126Multiple Myeloma

DrugsBelantamab mafodotin·Bortezomib·Lenalidomide·Dexamethasone

GlaxoSmithKline

Phase 1

118

Badalona, Barcelona, Madrid, Málaga, PamplonaNavarra, Pozuelo de AlarcOn Madr, Santander

2019-12-18

Recruiting

Terumo Aortic Global Endovascular Registry

NCT04246463Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery

Vascutek Ltd.

Observational

1,000

Badalona, Barcelona, Oviedo

2019-12-17

Active, closed

HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a)

NCT04257162Metastatic Cancer

SOLTI Breast Cancer Research Group

Not applicable

180

Badalona, Barcelona, Jerez de la Frontera, Santa Cruz de Tenerife, Lleida, Madrid, Seville, Valencia

2019-12-13

Recruiting

Abbott DBS Post-Market Study of Outcomes for Indications Over Time

NCT04071847Movement Disorders, Parkinson Disease, Essential Tremor, Tremor

Abbott Medical Devices

Observational

1,000

Seville, Badalona, Madrid

2019-11-26

Recruiting

Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

NCT04179929Acute Lymphoblastic Leukemia

PETHEMA Foundation

Not applicable

300

Badalona, A Coruña, Albacete, Alicante, Ávila, Barcelona, Bellvitge, Bilbao

2019-11-25

Active, closed

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

NCT04150068HIV-1-infection

DrugLenacapavir

Gilead Sciences

Phase 2/3

Badalona, Barcelona, Madrid, Seville

2019-11-21

Active, closed

Registry Study of Pregnancy and Breast Cancer

NCT04603820Breast Cancer and Pregnancy

Spanish Breast Cancer Research Group

Observational

866

Palma de Mallorca, Badalona, Terrassa, Bilbao, Santa Cruz de Tenerife, A Coruña, Las Palmas de Gran Canaria, Leganés

2019-11-18

Active, closed

NCT04232241Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes

Universitätsklinikum Hamburg-Eppendorf

Phase 2

167

Badalona, Barcelona, Madrid, Salamanca, Seville, Valencia

2019-11-14

Active, closed

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma

NCT04099251Melanoma

DrugsOpdivo·Nivolumab

Bristol-Myers Squibb

Phase 3

790

Barcelona, A Coruña, Badalona, Madrid, Málaga, Santander, Valencia

2019-10-28

Active, closed

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04126200Multiple Myeloma

DrugsFeladilimab·Nirogacestat·Belantamab mafodotin·Isatuximab

GlaxoSmithKline

Phase 1/2

208

Badalona, Madrid, PamplonaNavarra, Pozuelo de AlarcOn Madr

2019-10-07

Active, closed

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

NCT03989414Multiple Myeloma

DrugsElotuzumab·Mezigdomide·Isatuximab·Carfilzomib

Celgene

Phase 1/2

424

Badalona, Madrid, Málaga, Pamplona, Salamanca, Santander, Valencia

2019-09-30

Active, closed

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04033445Ulcerative Colitis

DrugGuselkumab

Janssen Research & Development, LLC

Phase 2/3

1,064

Badalona, Barcelona, Girona, Madrid, Santander, Seville

2019-09-26

Active, closed

Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

NCT04090736Leukemia, Myeloid, Acute

DrugAzacitidine

PETHEMA Foundation

Phase 3

302

Santiago de Compostela, Vitoria-Gasteiz, Badalona, Hospitalet Del Llobregat, San Sebastián, Jaén, Las Palmas de Gran Canaria, Pozuelo de Alarcón

2019-09-24

Active, closed

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

NCT04083339Diabetic Cardiomyopathies

Applied Therapeutics, Inc.

Phase 3

675

Badalona, El Palmar, A Coruña, Barcelona, Córdoba, Seville, Valencia

2019-09-20

Active, closed

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

NCT04119050Warm Autoimmune Hemolytic Anemia

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

118

Alcalá de Henares, Badalona, Barcelona, Burgos, Córdoba, Las Palmas de Gran Canaria, Madrid, Majadahonda

2019-08-15

Recruiting

Pan Tumor Rollover Study

NCT03899155Cancer

DrugsRucaparib·Sunitinib·Trametinib·Relatlimab

Bristol-Myers Squibb

Phase 2

1,500

Donostia / San Sebastian, Majadahonda, Pamplona, A Coruña, Alicante, Badalona, Barcelona, Burgos

2019-08-09

Recruiting

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

NCT04068597Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma

DrugsIxazomib·Elranatamab·Teclistamab·Pomalidomide

CellCentric Ltd.

Phase 1/2

250

Badalona, Barcelona, Madrid, Pamplona, Valencia

2019-08-09

Active, closed

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

NCT04008030Metastatic Colorectal Cancer

DrugsFluorouracil·Leucovorin·Ipilimumab·Irinotecan

Bristol-Myers Squibb

Phase 3

839

Badalona, A Coruña, Barcelona, Madrid, Málaga, Seville, Valencia

2019-08-05

Active, closed

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

NCT03924895Urinary Bladder Cancer, Muscle-invasive

DrugsEnfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

595

Badalona, Barcelona, Cáceres, Girona, Pozuelo de Alarcón, Valencia, Madrid, Seville

2019-07-24

Active, closed

Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

NCT03443856Gastric and Esophagogastric Junction Adenocarcinoma

DrugNivolumab and Ipilimumab

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2

197

Badalona, Madrid, Pamplona, Valencia

2019-07-17

Active, closed

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

NCT03960840Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia

DrugIbrutinib

Novartis Pharmaceuticals

Phase 1/2

217

Badalona, L'Hospitalet de Llobregat, Barcelona, Córdoba, Madrid, Salamanca, Seville, Valencia

2019-06-26

Active, closed

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

NCT03997123Triple Negative Breast Neoplasms

DrugsCapivasertib·Paclitaxel

AstraZeneca

Phase 3

923

Badalona, Barcelona, Hospitalet deLlobregat, Jaén, Madrid, Málaga, Seville, Valencia

2019-06-25

Recruiting

E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe

NCT03818503Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Observational

2,000

Badalona, Barcelona, Cartagena, Córdoba, Madrid, Pamplona, Salamanca, Terrassa

2019-06-24

Active, closed

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

NCT03969004Cutaneous Squamous Cell Carcinoma

DrugCemiplimab

Regeneron Pharmaceuticals

Phase 3

415

Barcelona, Alcorcón, Torrejón de Ardoz, Badalona, Madrid, Majadahonda, Salamanca, Seville

2019-06-04

Active, closed

NADIM II: Neo-Adjuvant Immunotherapy

NCT03838159Non Small Cell Lung Cancer

DrugsParaplatin·Taxol·Opdivo·Nivolumab

Fundación GECP

Phase 2

Alicante, Badalona, Barcelona, L'Hospitalet de Llobregat, Córdoba, Girona, Las Palmas de Gran Canaria, A Coruña

2019-05-15

Active, closed

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

NCT03675308Psoriatic Arthritis

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

964

Badalona, Sabadell, A Coruña, Almería, Barcelona, Madrid, Valencia

2019-03-25

Active, closed

Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.

NCT03869892Metastatic Colorectal Cancer

DrugsTrifluridine/Tipiracil·Capecitabine

Institut de Recherches Internationales Servier

Phase 3

856

Alicante, Badalona, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Santander, Seville

2019-03-21

Active, closed

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

NCT03836261Chronic Lymphocytic Leukemia

DrugsVenclyxto·Acalabrutinib·Venclexta·Obinutuzumab

Acerta Pharma BV

Phase 3

984

Badalona, Barcelona, Madrid, Majadahonda, Salamanca, Santander, Valencia

2019-02-25

Active, closed

Concordance Between FFR and iFR for the Assessment of Intermediate Lesions in the Left Main Coronary Artery. A Prospective Validation of a Default Value for iFR

NCT03767621Coronary Artery Disease, Left Main Coronary Artery Stenosis, Left Main Coronary Artery Disease, Restenosis, Coronary

Fundación EPIC

Observational

300

Terrassa, Cartagena, El Palmar, Castellon, Galdakao, Albacete, Badajoz, Badalona

2019-02-19

Active, closed

A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

NCT03796962Focal Epilepsy

DrugAzetukalner

Xenon Pharmaceuticals Inc.

Phase 2

325

Seville, Badalona, Pamplona, Barcelona, Granada, Madrid, Málaga, Valencia

2019-01-30

Recruiting

Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples

NCT04251078Myelodysplastic Syndromes

Josep Carreras Leukaemia Research Institute

Observational

200

Badalona

2019-01-01

Recruiting

Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy

NCT05674695Dermatitis, Atopic

DrugsCiclosporin·Omalizumab·Baricitinib·Upadacitinib

Fundación Academia Española de Dermatología

Observational

2,500

Badalona, Alicante, Barcelona, Las Palmas, Madrid, Pontevedra, Valencia, Zaragoza

2019-01-01

Active, closed

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918Head and Neck Neoplasms

DrugsKeytruda·Cisplatin·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

714

Badalona, L'Hospitalet de Llobregat, Santiago de Compostela, Barcelona, Madrid, Seville

2018-12-17

Active, closed

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334Early Breast Cancer

DrugRibociclib

Novartis Pharmaceuticals

Phase 3

5,101

Elche, Granada, Huelva, Jaén, Vitoria-Gasteiz, Badalona, L'Hospitalet de Llobregat, Manresa

2018-12-07

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/badalona

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 562 of those studies with a site in Badalona.

How many clinical trials are recruiting in Badalona?

257 of the 562 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 13 have not yet opened recruitment, 285 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Badalona), 562 studies
Phase	Studies	Recruiting	Share
Phase 3	263	102	46.8%
Phase 2	107	41	19%
Observational	64	42	11.4%
Phase 1/2	37	20	6.6%
Not applicable	32	24	5.7%
Phase 1	28	12	5%
Phase 2/3	24	12	4.3%
Phase 4	7	4	1.2%

Most active sponsors

Lead sponsors with the most studies (Badalona)
Lead sponsor	Studies	Recruiting
AstraZeneca	35	16
Janssen Research & Development, LLC	33	8
Merck Sharp & Dohme LLC	24	11
AbbVie	19	5
Bristol-Myers Squibb	17	8
Incyte Corporation	17	7
Novartis Pharmaceuticals	15	7
Pfizer	14	7
Fundación GECP	13	6
Regeneron Pharmaceuticals	12	5

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.